WO2021261444A1 - Tlr4作動活性を有するアジュバント - Google Patents
Tlr4作動活性を有するアジュバント Download PDFInfo
- Publication number
- WO2021261444A1 WO2021261444A1 PCT/JP2021/023402 JP2021023402W WO2021261444A1 WO 2021261444 A1 WO2021261444 A1 WO 2021261444A1 JP 2021023402 W JP2021023402 W JP 2021023402W WO 2021261444 A1 WO2021261444 A1 WO 2021261444A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- oxy
- tetradecanoyl
- Prior art date
Links
- 239000002671 adjuvant Substances 0.000 title claims description 16
- 230000000694 effects Effects 0.000 title description 23
- 239000000556 agonist Substances 0.000 title description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 212
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- 239000012646 vaccine adjuvant Substances 0.000 claims abstract description 19
- 229940124931 vaccine adjuvant Drugs 0.000 claims abstract description 19
- -1 decanoyloxy Chemical group 0.000 claims description 110
- 150000003839 salts Chemical class 0.000 claims description 103
- 108091007433 antigens Proteins 0.000 claims description 97
- 102000036639 antigens Human genes 0.000 claims description 97
- 239000000427 antigen Substances 0.000 claims description 79
- 125000000217 alkyl group Chemical group 0.000 claims description 55
- 125000003118 aryl group Chemical group 0.000 claims description 49
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 47
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 44
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 44
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 40
- 238000002360 preparation method Methods 0.000 claims description 39
- 244000052769 pathogen Species 0.000 claims description 38
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 37
- 230000001717 pathogenic effect Effects 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 28
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 208000035473 Communicable disease Diseases 0.000 claims description 17
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 17
- 239000002502 liposome Substances 0.000 claims description 16
- 229960005486 vaccine Drugs 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 14
- 235000019260 propionic acid Nutrition 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 7
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 6
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 235000005985 organic acids Nutrition 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- DAYFLFDXFQCPCQ-PSXMRANNSA-N [(2r)-2,3-di(tetradecoxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OCCCCCCCCCCCCCC DAYFLFDXFQCPCQ-PSXMRANNSA-N 0.000 claims description 3
- 210000002969 egg yolk Anatomy 0.000 claims description 3
- 235000013345 egg yolk Nutrition 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 33
- 235000002639 sodium chloride Nutrition 0.000 description 104
- 239000002904 solvent Substances 0.000 description 51
- 206010028980 Neoplasm Diseases 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 33
- 239000000243 solution Substances 0.000 description 31
- 239000007788 liquid Substances 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 24
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 24
- 238000006243 chemical reaction Methods 0.000 description 23
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 108010058846 Ovalbumin Proteins 0.000 description 19
- 229940092253 ovalbumin Drugs 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000003786 synthesis reaction Methods 0.000 description 14
- 201000011510 cancer Diseases 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 239000000839 emulsion Substances 0.000 description 12
- 239000002994 raw material Substances 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 11
- 230000002265 prevention Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 150000004665 fatty acids Chemical group 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 230000003287 optical effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000007764 o/w emulsion Substances 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 125000004797 2,2,2-trichloroethoxy group Chemical group ClC(CO*)(Cl)Cl 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 4
- 101100153375 Mus musculus Tlr4 gene Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940125773 compound 10 Drugs 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- WQZGKKKJIJFFOK-UHFFFAOYSA-N hexopyranose Chemical compound OCC1OC(O)C(O)C(O)C1O WQZGKKKJIJFFOK-UHFFFAOYSA-N 0.000 description 4
- 102000045717 human TLR4 Human genes 0.000 description 4
- 229930195733 hydrocarbon Natural products 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 4
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 238000003571 reporter gene assay Methods 0.000 description 4
- 229940095064 tartrate Drugs 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 239000007762 w/o emulsion Substances 0.000 description 4
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 230000010473 stable expression Effects 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- WLNJGOIHOQOCJP-JOCHJYFZSA-N (3r)-3-decanoyloxytetradecanoic acid Chemical compound CCCCCCCCCCC[C@H](CC(O)=O)OC(=O)CCCCCCCCC WLNJGOIHOQOCJP-JOCHJYFZSA-N 0.000 description 2
- IUBUFBCVRWLOCA-UHFFFAOYSA-N 2,3,6,7-tetramethylnaphthalene-1,4-dicarboxamide Chemical compound CC1=C(C)C(C(N)=O)=C2C=C(C)C(C)=CC2=C1C(N)=O IUBUFBCVRWLOCA-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 2
- AGSKWMRPXWHSPF-UHFFFAOYSA-M 3-(ethyliminomethylideneamino)propyl-trimethylazanium;iodide Chemical compound [I-].CCN=C=NCCC[N+](C)(C)C AGSKWMRPXWHSPF-UHFFFAOYSA-M 0.000 description 2
- RGUKYNXWOWSRET-UHFFFAOYSA-N 4-pyrrolidin-1-ylpyridine Chemical compound C1CCCN1C1=CC=NC=C1 RGUKYNXWOWSRET-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 2
- 208000006593 Urologic Neoplasms Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- VLNZUSMTOFYNPS-UHFFFAOYSA-N diethylphosphorylformonitrile Chemical compound CCP(=O)(CC)C#N VLNZUSMTOFYNPS-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 125000005956 isoquinolyl group Chemical group 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 125000005493 quinolyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- YMYLGVIBUGDMLT-QMMMGPOBSA-N (2s)-2-(phenylmethoxyamino)propanoic acid Chemical compound OC(=O)[C@H](C)NOCC1=CC=CC=C1 YMYLGVIBUGDMLT-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 0 *C(COC(C1NC(CC(*)O*)=O)OC(CO)C(*)C1OC(CC(*)O*)=O)NC(CC(*)O*)=O Chemical compound *C(COC(C1NC(CC(*)O*)=O)OC(CO)C(*)C1OC(CC(*)O*)=O)NC(CC(*)O*)=O 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- IRFSXVIRXMYULF-UHFFFAOYSA-N 1,2-dihydroquinoline Chemical compound C1=CC=C2C=CCNC2=C1 IRFSXVIRXMYULF-UHFFFAOYSA-N 0.000 description 1
- 125000005926 1,2-dimethylbutyloxy group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- RQEUFEKYXDPUSK-UHFFFAOYSA-N 1-phenylethylamine Chemical compound CC(N)C1=CC=CC=C1 RQEUFEKYXDPUSK-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 1
- ABFYEILPZWAIBN-UHFFFAOYSA-N 3-(iminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.CN(C)CCCN=C=N ABFYEILPZWAIBN-UHFFFAOYSA-N 0.000 description 1
- KLDLRDSRCMJKGM-UHFFFAOYSA-N 3-[chloro-(2-oxo-1,3-oxazolidin-3-yl)phosphoryl]-1,3-oxazolidin-2-one Chemical compound C1COC(=O)N1P(=O)(Cl)N1CCOC1=O KLDLRDSRCMJKGM-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- URWLWLXGACJYCO-UHFFFAOYSA-N 9-phenylnonanoic acid Chemical compound OC(=O)CCCCCCCCC1=CC=CC=C1 URWLWLXGACJYCO-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091008048 CMVpp65 Proteins 0.000 description 1
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 1
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 201000002563 Histoplasmosis Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
- 101001018020 Homo sapiens Lymphocyte antigen 96 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102100033467 L-selectin Human genes 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150067401 Ly96 gene Proteins 0.000 description 1
- 102100033446 Lymphocyte antigen 96 Human genes 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000003761 Vaginal carcinoma Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 159000000009 barium salts Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 description 1
- 235000000431 campesterol Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical compound O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000002554 disease preventive effect Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 102000046699 human CD14 Human genes 0.000 description 1
- 102000045711 human LY96 Human genes 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 150000002772 monosaccharides Chemical group 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WBGPDYJIPNTOIB-UHFFFAOYSA-N n,n-dibenzylethanamine Chemical compound C=1C=CC=CC=1CN(CC)CC1=CC=CC=C1 WBGPDYJIPNTOIB-UHFFFAOYSA-N 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- ANPWLBTUUNFQIO-UHFFFAOYSA-N n-bis(phenylmethoxy)phosphanyl-n-propan-2-ylpropan-2-amine Chemical compound C=1C=CC=CC=1COP(N(C(C)C)C(C)C)OCC1=CC=CC=C1 ANPWLBTUUNFQIO-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000001225 nuclear magnetic resonance method Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004262 preparative liquid chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Substances [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- VLYWMPOKSSWJAL-UHFFFAOYSA-N sulfamethoxypyridazine Chemical compound N1=NC(OC)=CC=C1NS(=O)(=O)C1=CC=C(N)C=C1 VLYWMPOKSSWJAL-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008307 w/o/w-emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
- C07H5/06—Aminosugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/248—Colchicine radicals, e.g. colchicosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
- C07H1/08—Separation; Purification from natural products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a compound useful as a vaccine adjuvant, a method for producing the same, a pharmaceutical composition containing the compound, and use of the compound as a vaccine adjuvant.
- Vaccines consisting of partial proteins or partial peptides derived from proteins produced by microorganisms can be produced by chemical synthesis or gene recombination technology, and are therefore excellent in terms of vaccine safety and production method.
- a vaccine tends to have a weaker medicinal effect than a live vaccine or an inactivated vaccine produced from bacterial cells as a raw material, and an adjuvant may be added for the purpose of enhancing immunogenicity.
- Alum has been widely used as an adjuvant for vaccines, but in recent years, 3-deacylated-4'-monophosphoryl lipid A (MPL), which is an agonist of Toll-like receptor 4 (TLR4), has been used as an adjuvant.
- MPL 3-deacylated-4'-monophosphoryl lipid A
- TLR4 Toll-like receptor 4
- TLR4 forms a heterodimer with MD-2 (myeloid differentiation factor-2) and activates the TLR4 pathway.
- LPS Lipid polysaccharide
- Non-Patent Document 2 lipid A structure consisting of a phosphorylated disaccharide and a fatty acid side chain. It has been reported that it plays an important role in heterodimer formation by interacting with both TLR4 and MD-2 (Non-Patent Document 3).
- the MPL is detoxified from LPS (Non-Patent Document 1), and MPL is a mixture of a plurality of compounds consisting of a phosphorylated disaccharide structure and a fatty acid side chain, similar to LPS (Non-Patent Document 4). .. It is known from the X-ray crystal structure that the phosphate group here interacts with both TLR4 and MD-2 (Non-Patent Document 3), and the activity is greatly attenuated when the phosphate group is removed from Lipid A. It is known to do so (Non-Patent Document 2). Further, the structure of the fatty acid here is also important for the TLR4 agonist activity, and it has been reported that it exhibits an antagonistic action depending on the structure of the fatty acid side chain (Non-Patent Document 2).
- Patent Documents 1 and 2 Since compounds derived from biological components such as MPL have problems in terms of production, studies on synthetic TLR4 agonists that imitate MPL are being conducted.
- AGP aminoalkylglucosamine phosphate
- the phosphorylated disaccharide structure which is the central structure, is converted into a phosphorylated monosaccharide structure, and there is phosphoric acid in AGP.
- the group is exemplified as an essential structure.
- the fatty acid side chain structure of AGP has been studied in detail, and it has been reported that the TLR4 agonist activity is lost when the fatty acid is converted as in the case of Lipid A (Non-Patent Document 5).
- TLR4 agonists having a structure containing a phosphate group such as AGP are considered to be disadvantageous in terms of production cost and stability during storage, but they have a central structure in various studies so far. There is no report of a vaccine adjuvant that does not contain a phosphate group and retains TLR4 agonist activity among TLR4 agonists having sugar and fatty acid side chains.
- An object of the present invention is to provide a TLR4 agonist having high adjuvant activity even if it does not contain a phosphate group.
- TLR4 agonist derivative represented by the following formula (1) (hereinafter, may be referred to as “compound of the present invention”) is provided.
- the present invention is as follows.
- Equation (1) [During the ceremony, A and A'independently represent hydrogen, hydroxy or-(CH 2 ) m- COOH, where at least one of A or A'represents-(CH 2 ) m- COOH.
- R 1 represents -C (O) (CH 2 ) n -X or -CH 2- (CH 2 ) n -X.
- R 2 represents -C (O) (CH 2 ) o -Y or -CH 2- (CH 2 ) o -Y.
- R 3 represents -C (O) (CH 2 ) p -Z or -CH 2- (CH 2 ) p -Z.
- X, Y, and Z are independent of methyl, C 6-10 aryl, respectively (the C 6-10 aryl is independent of hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy. It may be substituted with 1-5 substituents of choice) or 5-10 membered heteroaryls (the 5-10 membered heteroaryls are hydroxy, C 1-6 alkyl, halogen, cyano, and Represents ( may be substituted with 1 to 4 substituents independently selected from C 1-6 alkoxy), provided that at least one of X, Y or Z is C 6-10 aryl (the said.
- C 6-10 aryl may be substituted with 1-5 substituents independently selected from hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy) or 5– 10-membered heteroaryl (the 5-10-membered heteroaryl is substituted with 1 to 4 substituents independently selected from hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy.
- A is -COOH and the stereochemistry of * is the S configuration
- Y represents methyl
- Y represents methyl.
- R 4 , R 5 , and R 6 each independently represent C 10-20 alkyl.
- m independently represents an integer of 0 to 6 and represents n, o, and p each independently represent an integer of 5 to 20] or a pharmaceutically acceptable salt thereof.
- Item 2 The compound according to Item 1 or a pharmaceutically acceptable salt thereof, wherein m is 0.
- R 1 is -C (O) (CH 2 ) n -X
- R 2 is -C (O) (CH 2 ) o -Y
- R 3 is -C (O) (CH 2 ) p- Item 2.
- Item 5 The compound according to any one of Items 1 to 3, wherein A is COOH, or a pharmaceutically acceptable salt thereof.
- Item 5 The compound according to any one of Items 1 to 4, wherein A is COOH and A'is hydroxy, or a pharmaceutically acceptable salt thereof.
- Item 5 The compound according to any one of Items 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R 4 , R 5 and R 6 are independently C 10-12 alkyl.
- Equation (2) [During the ceremony, R 1 represents -C (O) (CH 2 ) n -X, R 2 represents -C (O) (CH 2 ) o -Y, R 3 represents -C (O) (CH 2 ) p -Z, X, Y, and Z each independently represent methyl, C 6-10 aryl or 5-10 membered heteroaryl, provided that at least one of X, Y, or Z is C 6-10 aryl or Represents a 5-10 member heteroaryl
- Y represents methyl
- R 4 , R 5 and R 6 each independently represent C 10-12 alkyl.
- n, o, and p each independently represent an integer of 6 to 10], which is the compound according to Item 1 or a pharmaceutically acceptable salt thereof.
- Equation (3) [During the ceremony, R 1 represents -C (O) (CH 2 ) n -X, R 2 represents -C (O) (CH 2 ) o -Y, R 3 represents -C (O) (CH 2 ) p -Z, X, Y, and Z each independently represent methyl, C 6-10 aryl or 5-10 membered heteroaryl, provided that at least one of X, Y, or Z is C 6-10 aryl or Represents a 5-10 member heteroaryl
- Y represents methyl
- n, o, and p each independently represent an integer of 6 to 10]
- Equation (4) or Equation (5) [During the ceremony, R 1 represents -C (O) (CH 2 ) n -X, R 2 represents -C (O) (CH 2 ) o -Y, R 3 represents -C (O) (CH 2 ) p -Z, R 2 'represents -C (O) (CH 2) o -CH 3, X, Y, and Z each independently represent methyl, C 6-10 aryl or 5-10 membered heteroaryl, provided that, in formula (4), at least one of X, Y, or Z.
- n, o, and p each independently represent an integer of 7 to 9], which is the compound according to Item 1 or a pharmaceutically acceptable salt thereof.
- X, Y, and Z are each independently methyl or phenyl, provided that at least one of X, Y, or Z is phenyl, where A is -COOH and * the stereochemistry.
- Y represents methyl, the compound according to any one of Items 1 to 9, or a pharmaceutically acceptable salt thereof.
- Item 11 The compound according to Item 1 or a pharmaceutically acceptable salt thereof selected from the following compound group: (2R) -2- ⁇ [(3R) -3- (decanoyloxy) tetradecanoyl] amino ⁇ -3- ⁇ [3- ⁇ [(3R) -3- (decanoyloxy) tetradecanoyl] amino ⁇ -5 Hydroxy-6- (hydroxymethyl) -4-( ⁇ (3R) -3-[(9-phenylnonanoyl) oxy] tetradecanoyl ⁇ oxy) oxane-2-yl] oxy ⁇ propanoic acid (Example 1) , (2S) -2- ⁇ [(3R) -3- (decanoyloxy) tetradecanoyl] amino ⁇ -3- ⁇ [3- ⁇ [(3R) -3- (decanoyloxy) tetradecanoyl] amino ⁇ -5 Hydroxy-6- (hydroxymethyl)
- Item 13 The pharmaceutical composition according to Item 12, which is a lipid preparation.
- Item 14 The pharmaceutical composition according to Item 12 or 13, wherein the lipid preparation is a liposome preparation containing a phospholipid.
- Item 12 The pharmaceutical composition according to Item 14, wherein the phospholipid is 1,2-dimyristyl-sn-glycero-3-phosphocholine and egg yolk phosphatidylglycerol.
- Item 14 or 15 which is a liposome preparation containing one or more additives selected from the group consisting of inorganic acids, inorganic acid salts, organic acids, organic acid salts, sugars, buffers, antioxidants, and polymers.
- additives selected from the group consisting of inorganic acids, inorganic acid salts, organic acids, organic acid salts, sugars, buffers, antioxidants, and polymers. The pharmaceutical composition described.
- Item 17 The pharmaceutical composition according to Item 17, wherein the antigen is a pathogen-derived antigen.
- a vaccine adjuvant comprising the compound according to any one of Items 1 to 11 or a pharmaceutically acceptable salt thereof.
- Item 19 The vaccine adjuvant according to Item 19, which is an adjuvant for an infectious disease vaccine.
- a therapeutic or prophylactic agent for an infectious disease which comprises a compound according to any one of Items 1 to 11 or a pharmaceutically acceptable salt thereof, which is used in combination with a pathogen-derived antigen.
- Item 5 The compound according to any one of Items 1 to 11, or a pharmaceutically acceptable salt thereof, which is used as a vaccine adjuvant.
- [Item 23] A method for enhancing a specific immune response against an antigen in a mammal, comprising administering to the mammal the compound according to any one of Items 1 to 11 or a pharmaceutically acceptable salt thereof.
- [Item 25] a) A pharmaceutical composition containing the compound represented by the formula (1) of Item 1 or a pharmaceutically acceptable salt thereof, or the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof; and b) an antigen.
- Item 25 The kit according to Item 25, wherein the antigen is a pathogen-derived antigen.
- the compound of the present invention is a compound having TLR4 agonistic activity without introducing a phosphate group on the sugar skeleton by conversion of side chain fatty acid, and is a compound having high adjuvant activity. Since it does not contain a phosphate group on the sugar skeleton, it is highly stable during storage, and since the introduction step of the phosphate group can be omitted, the production cost can be suppressed, which is very useful as a vaccine adjuvant.
- FIG. 1 is a graph showing the results of ELISA measurement of OVA-specific IgG2c in the serum of immune mice in mice intramuscularly administered with the formulations of Example 6 and Example 7 in Test Example 3.
- the vertical axis shows the antibody titer of serum OVA-specific IgG2c.
- the horizontal axis shows the sample administered (the dose in parentheses is the dose administered).
- FIG. 2 is a graph showing the results of ELISA-measurement of OVA-specific IgG2c in the serum of immune mice in mice intramuscularly administered with the formulations of Reference Example 16 and Example 6 in Test Example 3. The vertical axis shows the antibody titer of serum OVA-specific IgG2c.
- FIG. 3 is a graph showing the proportion of type 1 helper T cells in the spleen cells of mice intramuscularly administered with the formulations of Example 6 and Example 7 as a result of the evaluation carried out in Test Example 4.
- the horizontal axis is the same as in FIG. FIG.
- FIG. 4 is a graph showing the proportion of type 1 helper T cells in the spleen cells of mice intramuscularly administered with the formulations of Reference Example 16 and Example 6 as a result of the evaluation carried out in Test Example 4.
- the horizontal axis is the same as in FIG.
- FIG. 5 is a graph showing the ratio of OVA tetramer-positive CD8 T cells in the spleen cells of mice intramuscularly administered with the formulations of Example 6 and Example 7 as a result of the evaluation carried out in Test Example 4.
- the horizontal axis is the same as in FIG. FIG.
- FIG. 6 is a graph showing the ratio of OVA tetramer-positive CD8 T cells in the spleen cells of mice intramuscularly administered with the preparations of Reference Example 16 and Example 6 as a result of the evaluation carried out in Test Example 4.
- the horizontal axis is the same as in FIG.
- FIG. 7 is a graph showing the ratio of effector memory CD8T cells in the spleen cells of mice intramuscularly administered with the formulations of Example 6 and Example 7 as a result of the evaluation carried out in Test Example 4.
- the horizontal axis is the same as in FIG. FIG.
- FIG. 8 is a graph showing the ratio of effector memory CD8T cells in the spleen cells of mice intramuscularly administered with the formulations of Reference Example 16 and Example 6 as a result of the evaluation carried out in Test Example 4.
- the horizontal axis is the same as in FIG.
- the number of substituents in the group defined as “may be substituted” or “substituted” is not particularly limited as long as it can be substituted. Unless otherwise indicated, the description of each group also applies when the group is part of another group or a substituent.
- halogen examples include fluorine, chlorine, bromine, and iodine. Fluorine or chlorine is preferable, and fluorine is more preferable.
- C 1-6 alkyl means a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms.
- C 1-4 alkyl is preferable, and "C 1-3 alkyl” is more preferable.
- Specific examples of “C 1-6 alkyl” include, for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 2-methylpropyl, 1-methylpropyl, 1,1-dimethylethyl, pentyl, 3-methylbutyl, Examples thereof include 2-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, 1,1-dimethylpropyl, hexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl and 1-methylpentyl, and "C.
- 1-4 alkyl include examples of “C 1-6 alkyl” having 1 to 4 carbon atoms.
- C 1-3 alkyl include examples of the specific example of “C 1-6 alkyl” having 1 to 3 carbon atoms.
- C 1-6 alkoxy means “C 1-6 alkyloxy”, and the “C 1-6 alkyl” moiety is synonymous with the above “C 1-6 alkyl”.
- the "C 1-6 alkoxy” is preferably “C 1-4 alkoxy”, and more preferably “C 1-3 alkoxy”. Specific examples of "C 1-6 alkoxy” include, for example, methoxy, ethoxy, propoxy, 1-methylethoxy, butoxy, 2-methylpropoxy, 1-methylpropoxy, 1,1-dimethylethoxy, pentyroxy, 3-methyl.
- C 10-20 alkyl means a linear or branched saturated hydrocarbon group having 10 to 20 carbon atoms.
- “C 10-15 alkyl” is preferable, and “C 10-12 alkyl” is more preferable. Even more preferably, linear “C 10-12 alkyl” can be mentioned.
- Specific examples of the linear “C 10-20 alkyl” include decyl, undecylic, dodecyl, tridecylic, tetradecyl, pentadecylic, hexadecyl, heptadecyl, octadecyl, nonadecyl, and eicocil, and "C 10-15 alkyl".
- Specific examples of the above include examples of the specific example of "C 10-20 alkyl” having 10 to 15 carbon atoms.
- Specific examples of "C 10-12 alkyl” include examples of the specific example of "C 10-20 alkyl” having 10 to 12 carbon atoms.
- C 6-10 aryl means an aromatic hydrocarbon having 6 to 10 carbon atoms. Specific examples of “C 6-10 aryl” include, for example, phenyl, 1-naphthyl, 2-naphthyl and the like. More preferably, phenyl is mentioned.
- the "5- to 10-membered heteroaryl” is a monocyclic 5- to 7-membered aromatic heterocycle containing 1 to 4 atoms independently selected from the group consisting of nitrogen, oxygen and sulfur atoms. Examples include groups and 2-ring 8- to 10-membered aromatic heterocyclic groups.
- the "5- to 10-membered heteroaryl” is preferably a "5- to 7-membered heteroaryl", more preferably a 5- to 7-membered aromatic heterocycle having one or more nitrogen atoms in the ring (5-7 membered heteroaryl). "5-7 member nitrogen-containing heteroaryl").
- pyridyl pyridazinyl, isothiazolyl, pyrrolyl, frill, thienyl, thiazolyl, imidazolyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isooxazolyl, pyrazinyl, triazinyl, triazolyl, imidazolidinyl, oxadiazolyl.
- Specific examples of the "5- to 7-membered heteroaryl” include examples of a single ring in the above-mentioned specific example of the "5- to 10-membered heteroaryl".
- Specific examples of the "5- to 7-membered nitrogen-containing heteroaryl” include examples of the nitrogen-containing monocycle in the above-mentioned specific example of the "5- to 10-membered heteroaryl”.
- the C 6-10 aryl in the present invention may be substituted with 1-5 substituents independently selected from hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy.
- the 5- to 10-membered heteroaryl may be substituted with 1 to 4 substituents independently selected from hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy.
- the number of substituents that may be substituted on the C 6-10 aryl and the 5-10 membered heteroaryl is preferably 1 to 3, more preferably 1 to 2, and even more preferably 1. It is one.
- A, A', R 1 , R 2 , R 2' , R 3 , X, Y, Z, R 4 , R 5 , R. 6 , m, n, o, p, which are preferable, are as follows, but the technical scope of the present invention is not limited to the range of the compounds listed below.
- Preferred A is hydrogen, hydroxy or-(CH 2 ) m- COOH.
- A is hydrogen, hydroxy or-(CH 2 ) m- COOH.
- -(CH 2 ) m -COOH is more preferable, and -COOH is more preferable.
- Preferred A's include hydrogen, hydroxy or-(CH 2 ) m- COOH. Hydroxy is more preferably mentioned as A'.
- the combination of A and A' is preferably a combination in which at least one of A or A'is-(CH 2 ) m- COOH. More preferably, the combination of A and A'includes a combination in which A is- (CH 2 ) m-COOH and A'is hydroxy. More preferably, the combination of A and A'includes a combination in which A is -COOH and A'is hydroxy.
- R 1 examples include -C (O) (CH 2 ) n- X or -CH 2- (CH 2 ) n-X. More preferably, R 1 includes -C (O) (CH 2 ) n- X.
- R 2 examples include -C (O) (CH 2 ) o- Y or -CH 2- (CH 2 ) o-Y. More preferably, R 2 includes -C (O) (CH 2 ) o- Y.
- R 2' -C (O) (CH 2 ) o -CH 3 is preferable.
- R 3 examples include -C (O) (CH 2 ) p- Z or -CH 2- (CH 2 ) p-Z. More preferably, R 3 is -C (O) (CH 2 ) p- Z.
- X is preferably methyl, C 6-10 aryl (said C 6-10 aryl, hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 1 ⁇ 5 one independently selected from alkoxy It may be substituted with a substituent) or 5-10 membered heteroaryl (the 5-10 membered heteroaryl is independent of hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy. It may be substituted with 1 to 4 substituents selected in the above).
- the X is more preferably methyl or C 6-10aryl , even more preferably methyl or phenyl, and even more preferably phenyl.
- Y is preferably methyl, C 6-10 aryl (where C 6-10 aryl is 1-5 independently selected from hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy. It may be substituted with a substituent) or 5-10 membered heteroaryl (the 5-10 membered heteroaryl is independent of hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy. It may be substituted with 1 to 4 substituents selected in the above).
- Y is more preferably methyl or C 6-10 aryl, even more preferably methyl or phenyl, and even more preferably methyl.
- Z is preferably methyl, C 6-10 aryl (said C 6-10 aryl, hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 1 ⁇ 5 one independently selected from alkoxy It may be substituted with a substituent) or 5-10 membered heteroaryl (the 5-10 membered heteroaryl is independent of hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy. It may be substituted with 1 to 4 substituents selected in the above).
- Z is more preferably methyl or C 6-10aryl , even more preferably methyl or phenyl, and even more preferably methyl.
- the combination of X, Y, and Z is preferably at least one of X, Y, or Z with C 6-10 aryl (where C 6-10 aryl is hydroxy, C 1-6 alkyl, halogen, cyano, and C).
- 1-6 Alkoxy may be substituted with 1-5 substituents independently selected) or 5-10 membered heteroaryls (the 5-10 membered heteroaryls are hydroxy, C1- 6 alkyl, halogen, cyano, and a C 1-6 optionally substituted with 1-4 substituents independently selected from alkoxy), provided that, a is located at a -COOH * stereochemistry
- Y represents methyl and at least one of X or Z is C 6-10 aryl (the C 6-10 aryl is hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-.
- 6 Alkoxy may be substituted with 1-5 substituents independently selected) or 5-10 membered heteroaryls (the 5-10 membered heteroaryls are hydroxy, C 1-6 alkyl. , Halogen, cyano, and C 1-6 alkoxy may be substituted with 1 to 4 substituents independently selected). More preferably, as a combination of X, Y, and Z, at least one of X, Y, or Z is a C 6-10 aryl or a 5-10 membered heteroaryl, where A is -COOH *. Examples include combinations in which when the chemistry is in the S configuration, Y represents methyl and at least one of X or Z is a C 6-10 aryl or a 5-10 membered heteroaryl.
- Y represents methyl when at least one of X, Y, or Z is phenyl, where A is -COOH and the stereochemistry of * is the S configuration.
- X or Z in which at least one is phenyl.
- the combination of X, Y, and Z includes a combination in which X is phenyl and Y and Z are methyl.
- R 4 , R 5 and R 6 are preferably independently C 10-20 alkyl, more preferably C 10-15 alkyl , and even more preferably C 10-12 alkyl. And even more preferably, C 11 alkyl.
- the m is preferably an integer of 0 to 6, more preferably an integer of 0 to 1, and even more preferably 0.
- n, o and p are preferably an integer of 5 to 20 independently of each other, more preferably an integer of 6 to 10, still more preferably 7 to 9, and even more preferably. , 8.
- preferred embodiments of the compound include the following compounds or pharmaceutically acceptable salts thereof.
- A is hydrogen, hydroxy or-(CH 2 ) m- COOH;
- A' is hydrogen, hydroxy or-(CH 2 ) m- COOH;
- R 1 is -C (O) (CH 2 ) n -X or -CH 2- (CH 2 ) n -X;
- R 2 is -C (O) (CH 2 ) o -Y or -CH 2- (CH 2 ) o -Y;
- R 3 is -C (O) (CH 2 ) p -Z or -CH 2- (CH 2 ) p -Z;
- X, Y, and Z are independent of methyl, C 6-10 aryl, respectively (the C 6-10 aryl is independent of hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy.
- C 1-6 alkoxy may be substituted with 1 to 4 substituents independently selected); However, at least one of X, Y or Z is selected independently of C 6-10 aryl (the C 6-10 aryl is selected independently of hydroxy, C 1-6 alkyl, halogen, cyano, and C 1-6 alkoxy.
- (B) is -COOH; A'is hydroxy; R 1 is -C (O) (CH 2 ) n -X; R 2 is -C (O) (CH 2 ) o -Y; R 3 is -C (O) (CH 2 ) p -Z; X, Y, and Z are each independently methyl, C 6-10 aryl, or 5-10 membered heteroaryl; However, at least one of X, Y or Z is a C 6-10 aryl, or a 5-10 membered heteroaryl, where Y represents methyl when the stereochemistry of * is the S configuration; R 4 , R 5 , or R 6 are each independently an alkyl of C 10-12; n, o and p are each independently an integer of 6-10.
- a compound or pharmaceutically acceptable salt is
- One embodiment of the compound represented by the formula (1) includes the following (C).
- (C) A is -COOH; A'is hydroxy;
- R 1 is -C (O) (CH 2 ) n -X;
- R 2 is -C (O) (CH 2 ) o -Y;
- R 3 is -C (O) (CH 2 ) p -Z;
- X, Y, and Z are each independently methyl, C 6-10 aryl, or 5-10 membered heteroaryl;
- at least one of X, Y or Z is a C 6-10 aryl, or a 5-10 membered heteroaryl, where Y represents methyl when the stereochemistry of * is the S configuration;
- R 4, R 5 or R 6, are each independently a undecyl;
- n, o and p are each independently an integer of 6-10.
- a compound or pharmaceutically acceptable salt is
- (D) is -COOH; A'is hydroxy; R 1 is -C (O) (CH 2 ) n -X; R 2 is -C (O) (CH 2 ) o -Y; R 3 is -C (O) (CH 2 ) p -Z; X, Y, and Z are each independently methyl, C 6-10 aryl, or 5-10 membered heteroaryl; However, at least one of X, Y or Z is a C 6-10 aryl, or a 5-10 membered heteroaryl, where Y represents methyl when the stereochemistry of * is the S configuration; R 4, R 5 or R 6, are each independently a undecyl; n, o and p are each independently an integer of 7-9, A compound or pharmaceutically acceptable salt.
- One embodiment of the compound represented by the formula (1) includes the following compound group or a pharmaceutically acceptable salt thereof.
- the method for producing the compound of the present invention will be described below, but the method for producing the compound of the present invention is not limited thereto.
- the compound of the present invention represented by the formula (1) can be produced, for example, by the following production methods 1 to 3.
- the compound represented by the formula (1) can be produced, for example, by the following production method.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, A', m are synonymous with item 1, and PA and PA'are independent of hydrogen, respectively.
- Hydroxy, O-PG 4 or (CH 2 ) m- C (O) O-PG 5 , PG 1 and PG 2 each independently represent an amino protecting group, and PG 3 and PG 4 , Each independently represents a hydroxyl-protecting group, and PG 5 represents a carboxylic acid protecting group.
- the protecting groups represented by PG 1 , PG 2 , PG 3 , PG 4 , or PG 5 are Protective Groups in Organic Synthesis (by Theodora W. Greene, Peter GM Wuts, published by John Wiley & Sons, Inc.). The protecting group described in 1999) can be used.
- Compound a1 can be produced, for example, by the method described in WO98 / 50399 and the like.
- Compounds a2, a5, and a8 can be produced by the production methods 2 and 3 described later.
- Step 1-1 Compound a3 is produced by reacting compound a1 with compound a2 in the presence of an appropriate condensing agent in an appropriate solvent.
- the condensing agent is appropriately selected from the reagents exemplified below, and preferably carbodiimides, more preferably 1- [3- (dimethylamino) propyl] -3-ethylcarbodiimidemethiodide. It is preferably used in combination with N, N-dimethyl-4-aminopyridine (DMAP) or 4-pyrrolidinopyridine as an accelerator for the condensation reaction.
- the solvent used is appropriately selected from the solvents exemplified below, and preferably chloroform and dichloromethane.
- the reaction time is usually 5 minutes to 48 hours, preferably 1 hour to 24 hours.
- the reaction temperature is usually ⁇ 78 ° C. to 100 ° C., preferably 0 ° C. to 50 ° C.
- Step 1-2 Compound a4 is produced by deprotecting the amino protecting group PG 1 of compound a3. This step can be performed according to the method described in Protective Groups in Organic Synthesis (Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Step 1-3 Compound a6 is produced by reacting compound a4 with compound a5 in the presence of an appropriate condensing agent in an appropriate solvent.
- the condensing agent is appropriately selected from the reagents exemplified below, and preferably 1-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
- the solvent used is appropriately selected from the solvents exemplified below, and preferably chloroform and dichloromethane.
- the reaction time is usually 5 minutes to 48 hours, preferably 1 hour to 24 hours.
- the reaction temperature is usually ⁇ 78 ° C. to 100 ° C., preferably 0 ° C. to 50 ° C.
- Step 1-4 Compound a7 is produced by deprotecting the amino protecting group PG 2 of compound a6. This step can be performed according to the method described in Protective Groups in Organic Synthesis (Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- Step 1-5 Compound a9 is produced by reacting compound a7 with compound a8 by a method according to steps 1-3 described above.
- Step 1-6 When the compound represented by formula (1) is a protective group PG 3 of the compound a9, comprising OPG 4 and / or C (O) OPG 5 to PA and PA 'are further PG 4 and / or PG 5 Manufactured by deprotecting.
- This step can be performed according to the method described in Protective Groups in Organic Synthesis (Theodora W. Greene, Peter G. M. Wuts, published by John Wiley & Sons, Inc., 1999).
- the condensation with the compounds a2, a5 and a8 may be carried out simultaneously depending on the substituents, or the order may be changed.
- R 2 and R 3 are the same and R 5 and R 6 are the same
- the same protecting group can be used for PG 1 and PG 2
- steps 1-2 as shown below, can be used.
- Compound a9 can be produced from compound a3 by the two steps of Steps 1-3.
- the compound a2 described in the production method 1 can be produced, for example, by the following production method when R 1 is ⁇ C (O) (CH 2 ) n ⁇ X in the compound of the formula (1).
- the compound a5 when R 2 is -C (O) (CH 2 ) o -Y and the compound a8 when R 3 is -C (O) (CH 2 ) p -Z are also manufactured by the same manufacturing method. It is possible.
- X, R 4, n has the same meaning as in claim 1, j is an integer of 0 ⁇ 18, k is the n-j-2, PG 6 represents a protecting group of a carboxylic acid.
- Steps 2-1 to 2-3 are methods according to the manufacturing method described in, for example, US2008 / 0188566. Further, steps 2-4 and 2-5 are methods according to, for example, the manufacturing method described in WO2004 / 062599.
- the compound a2 described in the production method 1 can be produced, for example, by the following production method when R 1 is ⁇ CH 2- (CH 2 ) n ⁇ X in the compound of the formula (1).
- the compound a5 when R 2 is -CH 2 (CH 2 ) o- Y and the compound a8 when R 3 is -CH 2 (CH 2 ) p- Z can be produced by the same production method.
- PG 6 represents a protecting group of a carboxylic acid
- Step 3-1 is a reaction of reducing carboxylic acid to alcohol, and can be produced according to the method described in, for example, Experimental Chemistry Course, Vol. 5, Vol. 14, p11-p16 (edited by The Chemical Society of Japan, 2005). Further, steps 3-2 to 3-4 are methods according to the manufacturing method described in, for example, WO01 / 36433.
- Compound a2 can also be produced by the method described in Bioorg Med Chem Lett. 2015 Feb 1; 25 (3): 547-53.
- the base used in each step of each of the above production methods should be selected in a timely manner depending on the reaction, the type of the raw material compound, etc., for example, sodium bicarbonate, alkali bicarbonate such as potassium bicarbonate, sodium carbonate.
- Alkali carbonates such as potassium carbonate, sodium hydride, metal hydrides such as potassium hydride, sodium hydroxide, alkali metal hydroxides such as potassium hydroxide, sodium methoxydo, sodium t-butoxide
- Alkali metal alkoxides such as, butyl lithium, organic metal bases such as lithium diisopropylamide, triethylamine, diisopropylethylamine, pyridine, 4-dimethylaminopyridine (DMAP), 1,8-diazabicyclo [5.4.0]-.
- Examples include organic bases such as 7-Undecene (DBU).
- the condensing agent used in each step of each of the above production methods should be selected in a timely manner depending on the type of the raw material compound and the like, and for example, phosphate esters such as diethyl cyanophosphate and diphenylphosphoryl azide; 1-ethyl-.
- phosphate esters such as diethyl cyanophosphate and diphenylphosphoryl azide; 1-ethyl-.
- Carbodiimides such as 3- (3-dimethylaminopropyl) -carbodiimide hydrochloride (WSC ⁇ HCl), dicyclohexylcarbodiimide (DCC), 1- [3- (dimethylamino) propyl] -3-ethylcarbodiimidemethiodide; 2 , A combination of disulfides such as 2'-dipyridyl disulfide and phosphines such as triphenylphosphine; phosphorus halides such as N, N'-bis (2-oxo-3-oxazolidinyl) phosphinic chloride (BOPCl); azo Combinations of azodicarboxylic acid diesters such as diethyl dicarboxylic acid and phosphine such as triphenylphosphine; 2-halo-1-lower alkylpyridinium halides such as 2-chloro-1-methylpyridinium iodide;
- the solvent used in each step of each of the above production methods should be selected in a timely manner depending on the reaction, the type of raw material compound, etc., for example, alcohols such as methanol, ethanol and isopropanol, acetone, methyl ketone and the like. Ketones, halogenated hydrocarbons such as methylene chloride, chloroform, ethers such as tetrahydrofuran (THF), dioxane, aromatic hydrocarbons such as toluene and benzene, aliphatic hydrocarbons such as hexane and heptane.
- alcohols such as methanol, ethanol and isopropanol
- acetone methyl ketone
- Ketones halogenated hydrocarbons
- halogenated hydrocarbons such as methylene chloride, chloroform
- ethers such as tetrahydrofuran (THF), dioxane
- aromatic hydrocarbons such as toluene and
- Esters such as ethyl acetate, propyl acetate, amides such as N, N-dimethylformamide (DMF), N-methyl-2-pyrrolidone, sulfoxides such as dimethyl sulfoxide (DMSO), acetonitrile.
- DMF N, N-dimethylformamide
- DMSO dimethyl sulfoxide
- Dimethyl sulfoxide can be mentioned, and these solvents can be used alone or in combination of two or more. Further, depending on the type of reaction, organic bases or organic acids may be used as a solvent.
- the intermediate or final product in the above-mentioned production method appropriately converts its functional group, and in particular, extends various side chains from an amino group, a hydroxyl group, a carbonyl group, a halogen group, etc., and the same.
- Functional group conversion and side chain extension can be performed by common methods commonly used (see, eg, Comprehensive Organic Transformations, R.C. Larock, John Wiley & Sons Inc. (1999), etc.).
- Examples of the “pharmaceutically acceptable salt” include acid addition salts and base addition salts.
- an inorganic acid salt such as hydrochloride, hydrobromide, sulfate, hydroiodide, nitrate, phosphate, or citrate, oxalate, phthalate, etc.
- examples thereof include organic acid salts such as salts and camphor sulfonates
- examples of the base addition salt include inorganic base salts such as sodium salt, potassium salt, calcium salt, magnesium salt, barium salt and aluminum salt, or trimethylamine, triethylamine and pyridine.
- Picolin 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, tromethamine [tris (hydroxymethyl) methylamine], tert-butylamine, cyclohexylamine, dicyclohexylamine, N, N-dibenzylethylamine and other organic bases.
- Examples include salts, as well as amino acid salts such as basic or acidic amino acids such as arginine, lysine, ornithine, aspartic acid, or glutamic acid.
- Suitable and pharmaceutically acceptable salts of the starting and target compounds are conventional non-toxic salts, such as organic acid salts (eg, acetates, trifluoroacetates, maleates, fumarates).
- inorganic acid salts eg hydrochloride, hydrobromide, hydroiodide, etc.
- Acid addition salts such as sulfates, nitrates or phosphates), salts with amino acids (eg arginine, aspartic acid or glutamate), alkali metal salts (eg sodium or potassium salts) and alkaline earth metal salts.
- Metallic salts such as (eg calcium salt or magnesium salt), ammonium salts, or organic base salts (eg trimethylamine salt, triethylamine salt, pyridine salt, picolin salt, dicyclohexylamine salt or N, N'-dibenzylethylenediamine salt, etc.) Others, such as, can be appropriately selected by those skilled in the art.
- the compound of the present invention when it is desired to obtain a salt of the compound of the present invention, if the compound of the present invention is obtained in the form of a salt, it may be purified as it is, and if it is obtained in the form of a free form, it may be dissolved or suspended in a suitable organic solvent. It may be turbid and an acid or base may be added to form a salt by a usual method. Further, the compound of the present invention and a pharmaceutically acceptable salt thereof may exist in the form of a solvate with water or various solvents, and these adducts are also included in the present invention.
- the temperature at which the salt is formed is selected from the range from ⁇ 50 ° C. to the boiling point of the solvent, preferably from 0 ° C. to the boiling point of the solvent, and more preferably from room temperature to the boiling point of the solvent. In order to improve the optical purity, it is desirable to raise the temperature to near the boiling point of the solvent. When the precipitated salt is collected by filtration, it can be cooled if necessary to improve the yield.
- the amount of the optically active acid or amine used is preferably in the range of about 0.5 to about 2.0 equivalents, preferably about 1 equivalent with respect to the substrate.
- the crystals are placed in an inert solvent (for example, an alcohol solvent such as methanol, ethanol, 2-propanol, an ether solvent such as diethyl ether, an ester solvent such as ethyl acetate, a hydrocarbon solvent such as toluene, acetonitrile and the like. It can also be recrystallized from the aproton solvent of No. 1 or a mixed solvent of two or more kinds selected from the above solvents) to obtain a highly pure optically active salt. Further, if necessary, the optically resolved salt can be treated with an acid or a base by a usual method to obtain a free form.
- an inert solvent for example, an alcohol solvent such as methanol, ethanol, 2-propanol, an ether solvent such as diethyl ether, an ester solvent such as ethyl acetate, a hydrocarbon solvent such as toluene, acetonitrile and the like. It can also be recrystallized from the
- a deuterium converter obtained by converting any one or two or more H of the compound represented by the formula (1) into 2 H (D) is also included in the compound represented by the formula (1).
- the present invention includes a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof. Further, solvates such as these hydrates or ethanol solvates are also included. Further, the present invention includes all tautomers of the present invention compound (1), all existing stereoisomers, and crystalline forms of all modes.
- the compounds (1) of the present invention are optical isomers based on optically active centers, atropisomers based on axial or planar clarities generated by the constraint of intramolecular rotation, other steric isomers, and tectonicity. All possible isomers and mixtures thereof, including these, are included within the scope of the invention, although some are possible, such as isomers and geometric isomers.
- the mixture of optical isomers of the compound of the present invention can be produced according to a usual method.
- the manufacturing method include a method using a raw material having an asymmetric point, or a method of introducing an asymmetry in an intermediate stage.
- optical isomers can be obtained by using an optically active raw material or by performing optical resolution or the like at an appropriate stage in the manufacturing process.
- an optical division method for example, when the compound represented by the formula (1) or an intermediate thereof has a basic functional group, it is contained in an inert solvent (for example, an alcohol solvent such as methanol, ethanol, 2-propanol or the like).
- Ether solvent such as diethyl ether, ester solvent such as ethyl acetate, hydrocarbon solvent such as toluene, aproton solvent such as acetonitrile, or a mixed solvent of two or more selected from the above solvents
- Acids eg, monocarboxylic acids such as mandelic acid, N-benzyloxyalanine, lactic acid, tartrate acid, diisopropyridene tartrate acid such as o-diisopropyridene tartrate acid, dicarboxylic acid such as malic acid, solvent acid such as solvent, solvent and solvent).
- a diastereomer method for forming a salt using a solvent can be mentioned.
- an optically active amine for example, 1-phenylethylamine, quinine, quinidine, cinchonidine, cinchonine, strikinone
- optical resolution by forming a salt using an organic amine such as the above.
- the compound of the present invention represented by the formula (1) or an intermediate thereof can be separated and purified by a method known to those skilled in the art. Examples include extraction, partitioning, reprecipitation, column chromatography (eg, silica gel column chromatography, ion exchange column chromatography or preparative liquid chromatography) or recrystallization. Examples of the recrystallized solvent include an alcohol solvent such as methanol, ethanol or 2-propanol, an ether solvent such as diethyl ether, an ester solvent such as ethyl acetate, an aromatic hydrocarbon solvent such as benzene or toluene, and acetone.
- an alcohol solvent such as methanol, ethanol or 2-propanol
- an ether solvent such as diethyl ether
- an ester solvent such as ethyl acetate
- aromatic hydrocarbon solvent such as benzene or toluene
- acetone an aromatic hydrocarbon solvent
- a ketone solvent, a halogen solvent such as dichloromethane or chloroform, a hydrocarbon solvent such as hexane, an aproton solvent such as dimethylformamide or acetonitrile, water, or a mixed solvent thereof can be used.
- a halogen solvent such as dichloromethane or chloroform
- a hydrocarbon solvent such as hexane
- an aproton solvent such as dimethylformamide or acetonitrile
- water or a mixed solvent thereof
- the present invention provides a compound represented by the above-defined formula (1) or a pharmaceutically acceptable salt thereof, which is useful as a vaccine adjuvant, preferably a vaccine adjuvant for an infectious disease vaccine.
- the present invention also combines a pharmaceutically acceptable diluent or carrier with a pharmaceutical composition comprising the compound represented by the formula (1) defined above or a pharmaceutically acceptable salt thereof (hereinafter referred to as pharmaceutically acceptable salt). ,
- a pharmaceutical composition comprising the compound represented by the formula (1) defined above or a pharmaceutically acceptable salt thereof (hereinafter referred to as pharmaceutically acceptable salt).
- pharmaceutically acceptable salt a pharmaceutically acceptable salt thereof
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be used as an adjuvant for maintaining or enhancing the immunostimulatory activity of an active ingredient having immunostimulatory activity. That is, the compound of the present invention or a pharmaceutically acceptable salt thereof has an activity of inducing or enhancing an antigen-specific antibody, specifically, an antigen-specific IgG, and more particularly, a Th1-type antigen-specific IgG (for example, IgG2c). In addition, the compound of the present invention or a pharmaceutically acceptable salt thereof has an activity of increasing cytotoxic T cells (CTL).
- CTL cytotoxic T cells
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an activity of inducing CTL in a mammal or an activity of enhancing CTL induction in a mammal.
- the compounds of the invention or pharmaceutically acceptable salts thereof have the activity of increasing CD4 positive (ie, MHC class II binding) and / or CD8 positive (ie, MHC Class I binding) T cells.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an activity of increasing antigen-specific T cells.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an activity of increasing memory T cells, specifically CD8-positive effector memory T cells.
- an adjuvant compound having a TLR4 agonist activity containing the same number of moles of phosphoric acid structure and having an action of increasing CTL is administered. It has the characteristic that it is about the same as the case where it is used.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an activity of activating immunocompetent cells.
- the pharmaceutical composition of the present invention may contain an antigen, and examples of the antigen include tumor antigens and pathogen-derived antigens.
- the tumor antigen include a tumor antigen protein, a partial peptide derived from the tumor antigen protein, and the like, and a complex of these antigens and a carrier is also included in the category of antigens in the present specification.
- the pathogen-derived antigen include a pathogen antigen protein such as a virus or a bacterium, a partial peptide derived from the pathogen antigen protein, and the like, and a complex of these antigens and a carrier is also an antigen in the present specification. Is included in the category of.
- Such complexes include those in which an antigen (including, but not limited to, proteins and peptides) is chemically crosslinked with a protein as a carrier via a linker known to those skilled in the art, and the antigen is a virus-like particle. Examples include those included in (Virus-like Particle; VLP). Therefore, the compound of the present invention or a pharmaceutically acceptable salt thereof is useful as a drug for treating or preventing infectious diseases such as viruses or bacteria, or cancer when used in combination with the antigen. In addition, the compound of the present invention or a pharmaceutically acceptable salt thereof is useful as an adjuvant that enhances the therapeutic or preventive effect of an infectious disease such as a virus or a bacterium, or cancer when used in combination with the antigen.
- an antigen including, but not limited to, proteins and peptides
- VLP Virus-like Particle
- the route of administration of the pharmaceutical composition of the present invention includes, for example, parenteral administration, specifically, intravascular (for example, intravenous), subcutaneous, intradermal, intramuscular, nasal, lymph node, and transdermal administration. ..
- parenteral administration specifically, intravascular (for example, intravenous), subcutaneous, intradermal, intramuscular, nasal, lymph node, and transdermal administration. ..
- the pharmaceutical composition of the present invention may contain a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.
- Examples of the form of the pharmaceutical composition of the present invention include liquid preparations and the like.
- liquid preparation of the present invention examples include an aqueous solution preparation or an aqueous suspension, an oily solution preparation or an oily suspension, a lipid preparation, an emulsion preparation and the like.
- an antigen tumor antigen or pathogen-derived antigen
- a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is dissolved or dispersed in water. Examples include the above-mentioned preparations.
- an antigen for example, an antigen (tumor antigen or pathogen-derived antigen) and / or a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is dissolved or dispersed in an oily component.
- the prepared product can be mentioned.
- the lipid preparation include a liposome preparation containing an antigen (tumor antigen or pathogen-derived antigen) and / or a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof.
- the emulsion preparation for example, a preparation containing an aqueous solution and an oily composition containing an antigen (tumor antigen or pathogen-derived antigen) and / or a compound represented by the formula (1) or a pharmaceutically acceptable salt thereof.
- Additives used in the aqueous solution preparation or aqueous suspension of the present invention include, for example, purified water, water for injection, buffer, pH adjuster, stabilizer, tonicity agent, solubilizer or lysis aid. And so on.
- Additives used in the oily solution preparation or oily suspension of the present invention include, for example, buffers, pH adjusters, stabilizers, tonicity agents, animal and vegetable fats and oils, hydrocarbons, fatty acids, fatty acid esters. , Solubilizers, solubilizers and the like.
- the emulsion preparation of the present invention includes an oil-in-water emulsion (also referred to as O / W emulsion), a water-in-oil emulsion (also referred to as W / O emulsion), and an oil-in-water emulsion (W / O / W emulsion). Also referred to as) or an oil-in-water emulsion (also referred to as O / W / O emulsion) in oil can be used.
- the emulsion preparation of the present invention preferably includes a water-in-oil emulsion (W / O emulsion) or an oil-in-water emulsion (O / W emulsion).
- an oil-in-water emulsion (O / W emulsion) can be mentioned.
- the water-in-oil emulsion preparation of the present invention can be produced by emulsifying the aqueous phase and the oil phase by a known method.
- the antigen (tumor antigen or pathogen-derived antigen) and / or the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is the oil phase and water in the emulsion. It may be contained in either one or both of the phases.
- the oil-in-water emulsion preparation of the present invention can be produced by emulsifying the aqueous phase and the oil phase by a known method.
- the antigen tumor antigen or pathogen-derived antigen
- the compound represented by the formula (1) or a pharmaceutically acceptable salt thereof is the oil phase and the aqueous phase in the emulsion. It may be contained in either one or both of the above.
- the liposome means a microvesicle having an internal phase composed of a lipid multilayer such as a bilayer of an amphipathic lipid molecule (lipid bilayer).
- lipid bilayer lipid bilayer
- the lipid multilayer is preferably a lipid bilayer.
- the liposome preparation of the present invention contains an amphipathic lipid molecule.
- Amphiphile Lipid Molecule The liposome preparation of the present invention preferably contains one or more "phospholipids".
- the "phospholipid” include phosphatidylcholine, phosphatidylglycerol, phosphatidylate, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin and the like.
- Preferred examples of the "phospholipid” include phosphatidylcholine, phosphatidylglycerol, phosphatidylethanolamine, sphingomyelin, and phosphatidylserine. More preferably, the "phospholipid” includes phosphatidylcholine, sphingomyelin, phosphatidylserine, and phosphatidylglycerol.
- the liposome containing the compound of the present invention can contain sterols.
- sterols include cholesterol, ⁇ -citosterol, stigmasterol, campesterol, brush castelloll, ergosterol, fucostelloll and the like.
- Preferable examples of sterols include cholesterol.
- the liposome containing the compound of the present invention can contain a pharmaceutically acceptable additive.
- Additives include, for example, inorganic acids, inorganic acid salts, organic acids, organic acid salts, sugars, buffers, antioxidants, and polymers.
- the inorganic acid include phosphoric acid, hydrochloric acid, and sulfuric acid.
- the inorganic acid salt include sodium hydrogen phosphate, sodium chloride, ammonium sulfate, and magnesium sulfate.
- the organic acid include citric acid, acetic acid, succinic acid, and tartaric acid.
- Examples of the organic acid salt include sodium citrate, sodium acetate, disodium succinate, and sodium tartrate.
- saccharides include glucose, sucrose, mannitol, sorbitol, and trehalose.
- buffer include L-arginine, L-histidine, tromethamole (trishydroxymethylaminomethane, Tris) and salts thereof.
- Antioxidants include, for example, sodium sulfite, L-cysteine, sodium thioglycolate, sodium thiosulfate, ascorbic acid, and tocopherol.
- the polymers include polyvinyl alcohol, polyvinylpyrrolidone, carboxyvinyl polymer, and sodium carboxymethyl cellulose.
- the compound represented by the formula (1) described in the present specification, a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the present invention may be combined with other drugs in addition to the above-mentioned pathogen-derived antigen. Can be used.
- the pharmaceutical composition of the present invention may further contain other additives, and examples of the additives include surfactants, antioxidants, preservatives, and soothing agents.
- the compound of formula (1) or a pharmaceutically acceptable salt thereof can be administered simultaneously with the antigenic substance (immunogen) or at a time lag, and the dose thereof is usually about 0.1 ng for warm-blooded animals.
- Unit doses ranging from / kg to 100 mg / kg, which usually provide effective doses as vaccine adjuvants.
- Unit dosage forms such as injectables usually contain, for example, 1 ng to 250 mg of active ingredient. Preferably, it is used at a dose in the range of 1 ng to 50 mg / kg per day. However, this daily dose may also need to vary depending on the host receiving treatment, the specific route of administration and the severity of the disease being treated. Therefore, the optimal dose can also be determined by the individual patient or the practitioner treating the warm-blooded animal.
- treatment is used to include alleviating all or part of any, some or all of the symptoms of a disease, or blocking or delaying the progression of a condition. ..
- prevention means primary prevention (preventing the onset of the disease) or secondary prevention (after the onset of the disease, preventing recurrence in patients whose symptoms have been alleviated or cured. , Prevention of recurrence).
- an infectious disease has a stage of infection with a pathogen (bacteria, fungus, protozoan, virus, etc.) and a stage of onset, it includes both prevention of infection with the pathogen and prevention of onset after infection.
- prevention also includes the meaning of preventing the transmission of pathogens from humans to other mediator organisms.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an immunoadjugant activity in vitro or in vivo, it is intended to maintain or enhance the immunogenicity of a tumor antigen or a pathogen-derived antigen as a vaccine adjuvant. It is useful for.
- the compound of the present invention or a pharmaceutically acceptable salt thereof has an adjuvant activity of cell-mediated immunity in vitro or in vivo, it maintains the immunogenicity of a tumor antigen or a pathogen-derived antigen as a vaccine adjuvant. Useful for augmentation.
- the compound of the present invention or a pharmaceutically acceptable salt thereof acts as an immunostimulatory substance (immune stimulator) which is a therapeutic or prophylactic agent for a disease, that is, a substance that induces a tumor antigen or a pathogen-derived antigen-specific immune response. It can be used to maintain or improve.
- immunostimulatory substance immunostimulatory substance
- the composition is also an aspect of the present invention.
- the tumor antigen or pathogen-derived antigen is not particularly limited, but is derived from a tumor-derived antigen protein, a pathogen-derived antigen protein, a tumor-derived antigen peptide derived from the tumor-derived antigen protein, or a pathogen derived from the pathogen-derived antigen protein.
- examples thereof include antigenic peptides (partial peptides) and complexes of these with carriers.
- the compound of the invention or a pharmaceutically acceptable salt thereof is administered in combination with a pathogen-derived antigen protein or pathogen-derived antigen peptide for the prevention of an infectious disease to cause an infectious disease. Can be treated or prevented.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be administered in combination with a pathogen-derived antigen protein or a pathogen-derived antigen peptide for the treatment or prevention of infectious diseases to obtain a therapeutic or preventive effect on infectious diseases. Can be enhanced.
- infectious disease is not particularly limited, but is, for example, genital tract, vulgaris vulgaris, sole vulgaris, hepatitis B, hepatitis C, simple herpesvirus, infectious soft genus tumor, natural pox, human immunodeficiency.
- Viral diseases such as virus (HIV), human papillomavirus (HPV), RS virus, norovirus, cytomegalovirus (CMV), varicella herpes virus (VZV), rhinovirus, adenovirus, coronavirus, influenza, parainfluenza; tuberculosis , Mycobacterium abium, bacterial diseases such as Hansen's disease; fungal disease, chlamydia, candida, aspergillus, cryptococcus meningitis, pneumocystis carini, cryptospolidium disease, histoplasmosis, toxoplasmosis, malaria, tripanosoma infection and leashmania It is possible to prevent infections such as diseases.
- the active ingredient of the infectious disease preventive vaccine is not particularly limited, and examples thereof include substances derived from microorganisms / pathogens such as bacteria, fungi, protozoans, and viruses that cause infectious diseases, and examples thereof include antigen proteins and substances derived from the proteins. Examples thereof include antigenic peptides (partial peptides), polysaccharides, lipids, and combinations thereof, or combinations of substances and carriers derived from the above-mentioned microorganisms / pathogens.
- the viral antigen peptide derived from the viral antigen is not particularly limited, but for example, influenza matrix protein peptide 58-66 (Jager E et al., Int. J. Cancer 67: 54 (1996)), HPV16 E7 peptide 86. -93 (van Driel WJ et al., Eur. J. Cancer 35: 946 (1999)), HPV E7 peptide 12-20 (Scheibenbogen C et al., J. Immunother 23: 275 (2000)), HPV16 E7 peptide 11-20 (Smith JWI et al., J. Clin. Oncol.
- the compounds of the invention or pharmaceutically acceptable salts thereof are administered in combination with a tumor antigen protein or tumor antigen peptide for cancer immunotherapy to treat or prevent cancer.
- a tumor antigen protein or tumor antigen peptide for cancer immunotherapy to treat or prevent cancer.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be administered in combination with a tumor antigen protein or a tumor antigen peptide for cancer immunotherapy to enhance the therapeutic or preventive effect of cancer.
- cancer include leukemia, myelodystrophy syndrome, multiple myeloma, malignant lymphoma, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, and cervical cervix.
- Cancer ovarian cancer, brain tumor, bone cancer, pancreatic cancer, head and neck cancer, cutaneous or intraocular malignant melanoma, rectal cancer, anal cancer, testis cancer, oviductal carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, External pudendal carcinoma, Hodgkin's disease, non-Hojikin's lymphoma, esophageal cancer, small intestinal cancer, endocrine cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urinary tract cancer, penis cancer, acute myeloid leukemia, chronic myeloid leukemia , Acute lymphoblastic leukemia, Chronic or acute leukemia including chronic lymphocytic leukemia, Pediatric solid cancer, Lymphocytic lymphoma, Kidney or urinary tract cancer, Renal calcinoma, Central nervous system (CNS) tumor, Primary CNS Lymphoma, tumor neovascularization, spinal tumor, brain stem gliome, pituitary
- the carrier used in the present invention is a substance that chemically and / or physically binds an antigen protein or an antigen peptide, and examples thereof include proteins and lipids.
- the carrier is not particularly limited, but is, for example, CRM197 (Vaccine. 2013). Oct 1; 31 (42): 4827-33), KLH (Cancer Immunol Immunother. 2003 Oct; 52 (10): 608-16), virus-like particles (PLoS ONE 5 (3): e9809) and liposomes (J Liposome) Res. 2004; 14 (3-4): 175-89).
- the antigen protein can be prepared by cloning the cDNA encoding the antigen protein and expressing it in a host cell according to a basic book such as Molecular Cloning 2nd Edt., Cold Spring Harbor Laboratoy Press (1989).
- the synthesis of the antigenic peptide can be performed according to the method used in ordinary peptide chemistry.
- the synthesis method is described in the literature (Peptide Synthesis, Interscience, New York, 1966; The Proteins, Vol. 2, Academic Press Inc., New York, 1976) and the like. The method is mentioned.
- the antigen is not particularly limited as long as it is an antigen that can be used as an active ingredient of a vaccine, but the above-mentioned antigen protein, an antigen peptide (partial peptide) derived from the antigen protein, or the like, and further, these and a carrier. Examples include a complex and the like.
- a compound represented by the formula (1) for the production of a vaccine vaccine adjuvant, or a pharmaceutically acceptable salt thereof.
- the use of the compound represented by the above-defined formula (I) or a pharmaceutically acceptable salt thereof as a vaccine adjuvant in the production of a vaccine for the treatment of infectious diseases is used. offer.
- a step of administering to a patient a compound represented by the above-defined formula (I) or a pharmaceutically acceptable salt thereof together with a tumor-derived antigen or a pathogen-derived antigen is included.
- it provides a method for treating, preventing or preventing the progression of an infectious disease.
- treatment and progression of an infectious disease which comprises a step of administering to a patient a compound represented by the above-defined formula (I) or a pharmaceutically acceptable salt thereof together with a pathogen-derived antigen.
- prevention or preventive measures are provided.
- Troc 2,2,2-trichloroethoxycarbonyl group
- TBS tert-butyldimethylsilyl group
- Bn benzyl group
- Fmoc 9-fluorenylmethyloxycarbonyl
- Boc tert-butoxycarbonyl
- Alko p -Alkoxybenzyl alcohol
- PEG polyethylene glycol tBu: tert-butyl HBTU: O- (benzotriazole-1-yl) -N, N, N', N'-tetramethyluronium hexafluorophosphart
- DIPEA N, N- Diisopropylethylamine
- DMF N, N-dimethylformamide
- TFA Trifluoroacetate
- TIS Triisopropylsilane
- LCMS liquid chromatographic mass spectrometry
- reaction solution was extracted with water / ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate, and the residue obtained by concentration was purified by silica gel column chromatography (eluting solvent; hexane: ethyl acetate) to purify the compound (676 mg). ) Was obtained.
- Reference example 2 (3R) -3-[(9-Phenylnonanoyl) oxy] tetradecanoic acid
- Zinc powder (672 mg) was added to a solution of the compound (676 mg) of Reference Example 1 in acetic acid (15 mL), and the mixture was stirred at 60 ° C. for 4 hours.
- the reaction solution was filtered through Celite, and the residue obtained by concentration was purified by silica gel column chromatography (eluting solvent; chloroform: methanol) to obtain the compound (451 mg) of the subject.
- reaction solution was stirred at room temperature for 18 hours and then extracted with water / chloroform.
- organic layer was dried over anhydrous magnesium sulfate, and the concentrated residue was purified by silica gel column chromatography (eluting solvent; hexane: ethyl acetate) to obtain the compound Q1 (1.62 g) of the subject.
- reaction solution was filtered through Celite and extracted with water / ethyl acetate.
- organic layer was dried over anhydrous magnesium sulfate and concentrated, and the obtained residue was purified by silica gel column chromatography (eluting solvent; hexane: ethyl acetate) to obtain the compound Q3 (114 mg) of the subject.
- Reference example 5-8 The compounds shown in Table 1 were obtained by reacting and treating with the corresponding raw materials in the same manner as in Reference Example 3 or 4.
- Example 1 (2R) -2- ⁇ [(3R) -3- (decanoyloxy) tetradecanoyl] amino ⁇ -3- ⁇ [3- ⁇ [(3R) -3- (decanoyloxy) tetradecanoyl] amino ⁇ -5 Hydroxy-6- (hydroxymethyl) -4-( ⁇ (3R) -3-[(9-phenylnonanoyl) oxy] tetradecanoyl ⁇ oxy) oxane-2-yl] oxy ⁇ propanoic acid THF (2 mL) was added to the compound of Reference Example 3 (33 mg) and 10% palladium carbon (25.9 mg), and the mixture was stirred at room temperature for 8 hours under a hydrogen atmosphere at 1 atm.
- reaction mixture was filtered through Celite and concentrated, then THF (1 mL) and TFA (0.1 mL) were added, and the mixture was stirred at room temperature for 3 hours. After completion of the reaction, the mixture was neutralized with an aqueous sodium hydrogen carbonate solution, extracted with chloroform, dried over anhydrous magnesium sulfate, and concentrated. The obtained residue was purified by silica gel column chromatography (eluting solvent; chloroform: methanol) to obtain the compound of the subject (5.1 mg).
- the human TLR4 reporter gene assay HEK-Blue TM hTLR4 cell line (Invivogen) is a stable expression of human TLR4, MD2, CD14 and secretory alkaline phosphatase (SEAP) reporter genes under transcriptional control of NF- ⁇ B response elements. It is a co-transfected cell line. TLR4 expression in this cell line has been tested by RT-PCR, flow cytometry. Stable expression transformants were selected using the antibiotic HEK-Blue TM Selection. TLR signaling leads to NF- ⁇ B translocation and promoter activation results in SEAP gene expression. The cells were incubated with the compounds synthesized in Examples and References at 37 ° C.
- Mouse TLR4 reporter gene assay HEK-Blue TM mTLR4 cell line (Invivogen) is a stable co-transfected cell line expressing mouse TLR4, MD2, CD14 and secretory SEAP reporter genes under transcriptional control of NF- ⁇ B response elements. It is a stock. TLR4 expression in this cell line has been tested by RT-PCR, flow cytometry. Stable expression transformants were selected using the antibiotic HEK-Blue TM Selection. TLR signaling leads to NF- ⁇ B translocation and promoter activation results in SEAP gene expression. The cells were incubated with the compounds synthesized in Examples and References at 37 ° C.
- TLR4 specific activation was evaluated.
- the degree of mouse TLR4 activation of the compounds of the invention was assessed using the mouse TLR4 reporter gene assay to determine the concentration of the compound resulting in half the maximum level of LPS-induced SEAP (EC 50 ).
- Test Examples 1 and 2 are shown in Tables 5 and 6.
- the compound of Reference Example 10 was not detected.
- the compound of Reference Example 10 was not liposomalized and was considered to have been trapped in the extruder membrane.
- the liposome was diluted 10-fold with purified water, and the average particle size, polydispersity index and zeta potential were measured by a dynamic light scattering method (ZETASIZER Nano-ZS, manufactured by Malvern).
- ZETASIZER Nano-ZS manufactured by Malvern
- the formulations of Examples 6 and 7 and Reference Example 16 were quantified by high performance liquid chromatography (HPLC).
- Ovalbumin (OVA) (2 mg / mL) as an antigen and the preparation prepared in Example 6, Example 7, or Reference 16 in 7-week-old C57BL / 6 male mice (Example 1, Example).
- An equal volume mixture (100 ⁇ L / mouse) containing 0.2 or 2 mg / mL of the compound of Reference Example 9 was intramuscularly administered to the gastrocnemius muscle for initial immunization.
- an equal amount of the same mixture was intramuscularly administered to the gastrocnemius muscle for booster immunization.
- cardiac blood was collected under maintenance of isoflurane inhalation anesthesia, and serum was collected by centrifugation.
- OVA-specific IgG2c levels in serum were quantified by the following ELISA method. That is, after adding OVA solution (SIGMA) to a 96-well plate, blocking with 1% skim milk (Wako), adding a serum sample diluted with phosphate buffer, and then adding a secondary antibody, goat anti-mouse. After IgG2c (Southern Bio) was added and SureBlue® TMB Micrewell Peroxidase Substrate (KPL) was added, the product of the enzymatic reaction was measured and quantified with a microplate reader. The results are shown in FIGS. 1 and 2. In Example 1, Example 2 and Reference Example 9, significantly stronger OVA-specific IgG2c induction was shown compared to the negative control group.
- SIGMA OVA solution
- Wako skim milk
- KPL SureBlue® TMB Micrewell Peroxidase Substrate
- Test Example 4 Ovalbumin (OVA) (2 mg / mL) prepared in Test Example 3 and the preparation prepared in Example 6, Example 7, or Reference Example 16 (compounds of Example 1, Example 2 or Reference Example 9 are 0.2. Or, an equal volume mixture (containing 2 mg / mL) (100 ⁇ L / mouse) was administered to the mice to prepare their spleen cells, and OVA and Breferdin A (eBioscience) were added and then cultured overnight.
- OVA Ovalbumin
- Cells were harvested, stained with APC-labeled anti-mouse CD3e antibody (invitrogen), PerCP-labeled anti-mouse CD4 antibody (BioLegend) and Fixable Viability Dye eFluor TM 520 (invitorgen), and then fixed with Fixation / Permeabilization buffer (invitrogen). Cells were treated with Permeabilization buffer (invitrogen) and then stained with antibody cocktail BV421-labeled anti-IFN- ⁇ antibody (BioLegend), PE-Cy7-labeled anti-IL-2 antibody (eBioscience) and PE-labeled TNF- ⁇ (BioLegend).
- the above spleen cells were subjected to V450-labeled anti-mouse CD3e antibody (invitrogen), Alexa Fluor® 647-labeled anti-mouse CD8 antibody (MBL), PE-Cy7-labeled anti-mouse CD44 antibody (invitrogen), PerCP-Cy5. Stained with 5-labeled anti-mouse CD62L antibody (invitrogen) and Fixable Viability dye eFluor 520 (invitrogen). Data acquisition and analysis were performed using FACS Cant II (BD Biosciences) and FLOWJO software (TreeStar). The results are shown in FIGS. 7 and 8.
- Example 1 The compounds of Example 1, Example 2 and Reference Example 9 were OVA-specific type 1 helper T cells, especially the proportion of OVA-specific multifunctional CD4-positive T lymphocytes and MHC-restricted OVA-specific CD8-positive T lymphocytes ( The proportion of OVA tetramer-positive CD8 T cells in FIGS. 5 and 6 and the proportion of CD8-positive effector memory T lymphocytes were significantly increased compared to the negative control group.
- the compound of the present invention is useful as an adjuvant that enhances the immunostimulatory action of a vaccine preparation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
一方、AGPを初めとするリン酸基を含んだ構造の合成TLR4アゴニストは、製造コスト面や保存時の安定性の面で不利と考えられるが、これまで種々検討されている中で、中心構造に糖及び脂肪酸側鎖を有するTLR4アゴニストにおいて、リン酸基を含まず、かつTLR4アゴニスト活性を保持したワクチンアジュバントの報告はない。
式(1):
A及びA’は各々独立して、水素、ヒドロキシ又は-(CH2)m-COOHを表し、ただし、A又はA’の少なくとも1つは-(CH2)m-COOHを表し、
R1は-C(O)(CH2)n-X又は-CH2-(CH2)n-Xを表し、
R2は-C(O)(CH2)o-Y又は-CH2-(CH2)o-Yを表し、
R3は-C(O)(CH2)p-Z又は-CH2-(CH2)p-Zを表し、
X、Y、及びZは各々独立して、メチル、C6-10アリール(該C6-10アリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~5個の置換基で置換されていてもよい)又は5~10員のヘテロアリール(該5~10員のヘテロアリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~4個の置換基で置換されていてもよい)を表し、ただし、X、Y又はZのうち少なくとも一つはC6-10アリール(該C6-10アリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~5個の置換基で置換されていてもよい)又は5~10員のヘテロアリール(該5~10員のヘテロアリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~4個の置換基で置換されていてもよい)を表し、
ここにおいて、Aが-COOHであり*の立体化学がS配置のとき、Yはメチルを表し、
R4、R5、及びR6は各々独立して、C10-20アルキルを表し、
mは各々独立して0~6の整数を表し、
n、o、及びpは各々独立して5~20の整数を表す]で示される化合物又はその製薬学的に許容される塩。
mが0である、項1に記載の化合物又はその製薬学的に許容される塩。
R1が-C(O)(CH2)n-Xであり、R2が-C(O)(CH2)o-Yであり、R3が-C(O)(CH2)p-Zである、項1又は2に記載の化合物又はその製薬学的に許容される塩。
AがCOOHである、項1~3のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
AがCOOHであり、A’がヒドロキシである、項1~4のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
R4、R5、及びR6が各々独立して、C10-12アルキルである、項1~5のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
式(2):
R1は-C(O)(CH2)n-Xを表し、
R2は-C(O)(CH2)o-Yを表し、
R3は-C(O)(CH2)p-Zを表し、
X、Y、及びZは各々独立して、メチル、C6-10アリール又は5~10員のヘテロアリールを表し、ただし、X、Y、又はZのうち少なくとも一つはC6-10アリール又は5~10員のヘテロアリールを表し、
ここにおいて、*の立体化学がS配置のとき、Yはメチルを表し、
R4、R5、及びR6が各々独立して、C10-12アルキルを表し、
n、o、及びpは各々独立して6~10の整数を表す]で示される、項1に記載の化合物又はその製薬学的に許容される塩。
式(3):
R1は-C(O)(CH2)n-Xを表し、
R2は-C(O)(CH2)o-Yを表し、
R3は-C(O)(CH2)p-Zを表し、
X、Y、及びZは各々独立して、メチル、C6-10アリール又は5~10員のヘテロアリールを表し、ただし、X、Y、又はZのうち少なくとも一つはC6-10アリール又は5~10員のヘテロアリールを表し、
ここにおいて、*の立体化学がS配置のとき、Yはメチルを表し、
n、o、及びpは各々独立して6~10の整数を表す]で示される、項1に記載の化合物又はその製薬学的に許容される塩。
式(4)又は式(5):
R1は-C(O)(CH2)n-Xを表し、
R2は-C(O)(CH2)o-Yを表し、
R3は-C(O)(CH2)p-Zを表し、
R2’は-C(O)(CH2)o-CH3を表し、
X、Y、及びZは各々独立して、メチル、C6-10アリール又は5~10員のヘテロアリールを表し、ただし、式(4)においては、X、Y、又はZのうち少なくとも一つはC6-10アリール又は5~10員のヘテロアリールを表し、式(5)においては、X又はZの少なくとも一つはC6-10アリール又は5~10員のヘテロアリールを表し、
n、o、及びpは各々独立して7~9の整数を表す]で示される、項1に記載の化合物又はその製薬学的に許容される塩。
X、Y、及びZが各々独立して、メチル又はフェニルであり、ただし、X、Y、又はZのうち少なくとも1つはフェニルであり、ここにおいて、Aが-COOHであり*の立体化学がS配置のときのとき、Yはメチルを表す、項1~9のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
以下の化合物群から選択される、項1に記載の化合物又はその製薬学的に許容される塩:
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例1)、
(2S)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例2)、
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[4-{[(3R)-3-(デカノイロキシ)テトラデカノイル]オキシ}-5-ヒドロキシ-6-(ヒドロキシメチル)-3-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)オキサン-2-イル]オキシ}プロパン酸(実施例3)、
(2R)-2-({[(3R)-3-(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-(デカノイロキシ)テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例4)、及び
(2S)-2-({[(3R)-3-(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-(デカノイロキシ)テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例5)。
項1~11のいずれか一項に記載の化合物又はその製薬学的に許容される塩を含有する医薬組成物。
脂質製剤である、項12に記載の医薬組成物。
脂質製剤が、リン脂質を含むリポソーム製剤である、項12又は13に記載の医薬組成物。
リン脂質が、1,2-ジミリストイル-sn-グリセロ-3-ホスホコリン及び卵黄ホスファチジルグリセロールである、項14に記載の医薬組成物。
無機酸、無機酸塩、有機酸、有機酸塩、糖類、緩衝剤、酸化防止剤、及びポリマー類からなる群から選択される1以上の添加物を含むリポソーム製剤である、項14または15に記載の医薬組成物。
更に抗原を含有する、項12~16のいずれか一項に記載の医薬組成物。
抗原が、病原体由来抗原である、項17に記載の医薬組成物。
項1~11のいずれか一項に記載の化合物又はその製薬学的に許容される塩を含む、ワクチンアジュバント。
感染症ワクチンのアジュバントである、項19に記載のワクチンアジュバント。
病原体由来抗原と併用される、項1~11のいずれか一項に記載の化合物又はその製薬学的に許容される塩を含む、感染症の治療または予防剤。
ワクチンアジュバントとして用いられる、項1~11のいずれか一項に記載の化合物またはその製薬学的に許容される塩。
項1~11のいずれか一項に記載の化合物またはその薬学上許容される塩を哺乳動物に投与することを含む、哺乳動物における抗原に対する特異的免疫応答を増強する方法。
項1~11のいずれか一項に記載の化合物もしくはその薬学上許容される塩の、ワクチンアジュバントを製造するための使用。
a)項1の式(1)で示される化合物又はその薬学上許容し得る塩、もしくは式(1)で示される化合物又はその薬学上許容し得る塩を含有する医薬組成物;および
b)抗原を含有する医薬組成物
を含有するキット。
抗原が、病原体由来抗原である、項25に記載のキット。
「5~10員のヘテロアリール」として具体的には、ピリジル、ピリダジニル、イソチアゾリル、ピロリル、フリル、チエニル、チアゾリル、イミダゾリル、ピリミジニル、チアジアゾリル、ピラゾリル、オキサゾリル、イソオキサゾリル、ピラジニル、トリアジニル、トリアゾリル、イミダゾリジニル、オキサジアゾリル、トリアゾリル、テトラゾリル、インドリル、インダゾリル、キノリル、イソキノリル、ベンゾフラニル、ベンゾチエニル、ベンゾオキサゾリル、ベンゾチアゾリル、ベンズイソオキサゾリル、ベンズイソチアゾリル、ベンゾトリアゾリル、ベンズイミダゾリル、又は6,11-ジヒドロジベンゾ[b,e]チエピニル等が挙げられる。好ましくは、ピリジル、ピリミジニル、キノリル、及びイソキノリルであり、さらに好ましくは、ピリジルである。
「5~7員のヘテロアリール」の具体的としては、上記「5~10員のヘテロアリール」の具体例における単環の例示が挙げられる。「5~7員の含窒素ヘテロアリール」の具体例としては、上記「5~10員のヘテロアリール」の具体例における、含窒素単環の例示が挙げられる。
X、Y、およびZの組み合わせとしてより好ましくは、X、Y又はZのうち少なくとも一つがC6-10アリール又は5~10員のヘテロアリールであり、ただし、Aが-COOHであり*の立体化学がS配置のとき、Yがメチルを表し、X又はZの少なくとも一つがC6-10アリール又は5~10員のヘテロアリールである組み合わせが挙げられる。
X、Y、およびZの組み合わせとして更に好ましくは、X、Y又はZのうち少なくとも一つがフェニルであり、ただし、Aが-COOHであり*の立体化学がS配置のとき、Yがメチルを表し、X又はZの少なくとも一つがフェニルである組み合わせが挙げられる。
X、Y、およびZの組み合わせとして更により好ましくは、Xがフェニルであり、YおよびZがメチルである組み合わせが挙げられる。
(A)
Aが、水素、ヒドロキシ又は-(CH2)m-COOHであり;
A’が、水素、ヒドロキシ又は-(CH2)m-COOHであり;
ただし、AまたはA’の少なくとも一方は-(CH2)m-COOHであり;
R1が、-C(O)(CH2)n-X、又は-CH2-(CH2)n-Xであり;
R2が、-C(O)(CH2)o-Y、又は-CH2-(CH2)o-Yであり;
R3が、-C(O)(CH2)p-Z、又は-CH2-(CH2)p-Zであり;
X、Y、及びZが、各々独立して、メチル、C6-10アリール(該C6-10アリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~5個の置換基で置換されていてもよい)、又は5~10員のヘテロアリール(該5~10員のヘテロアリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、C1-6アルコキシから独立して選択される1~4個の置換基で置換されていてもよい)であり;
ただし、X、Y又はZのうち少なくとも一つはC6-10アリール(該C6-10アリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~5個の置換基で置換されていてもよい)又は5~10員のヘテロアリール(該5~10員のヘテロアリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~4個の置換基で置換されていてもよい)であり、ここにおいて、Aが-COOHであり*の立体化学がS配置のとき、Yはメチルを表し;
R4、R5、またはR6が、各々独立して、C10-20アルキルであり;
mが各々独立して、0~6の整数であり;
n、o及びpが、各々独立して、5~20の整数である、
化合物または製薬学的に許容される塩。
(B)
Aが、-COOHであり;
A’がヒドロキシであり;
R1が、-C(O)(CH2)n-Xであり;
R2が、-C(O)(CH2)o-Yであり;
R3が、-C(O)(CH2)p-Zであり;
X、Y、及びZが、各々独立して、メチル、C6-10アリール、又は5~10員のヘテロアリールであり;
ただし、X、Y又はZのうち少なくとも一つはC6-10アリール、又は5~10員のヘテロアリールであり、ここにおいて、*の立体化学がS配置のとき、Yはメチルを表し;
R4、R5、またはR6が、各々独立して、C10-12のアルキルであり;
n、o及びpが、各々独立して、6~10の整数である、
化合物または製薬学的に許容される塩。
(C)
Aが、-COOHであり;
A’がヒドロキシであり;
R1が、-C(O)(CH2)n-Xであり;
R2が、-C(O)(CH2)o-Yであり;
R3が、-C(O)(CH2)p-Zであり;
X、Y、及びZが、各々独立して、メチル、C6-10アリール、又は5~10員のヘテロアリールであり;
ただし、X、Y又はZのうち少なくとも一つはC6-10アリール、又は5~10員のヘテロアリールであり、ここにおいて、*の立体化学がS配置のとき、Yはメチルを表し;
R4、R5、またはR6が、各々独立して、ウンデシルであり;
n、o及びpが、各々独立して、6~10の整数である、
化合物または製薬学的に許容される塩。
(D)
Aが、-COOHであり;
A’がヒドロキシであり;
R1が、-C(O)(CH2)n-Xであり;
R2が、-C(O)(CH2)o-Yであり;
R3が、-C(O)(CH2)p-Zであり;
X、Y、及びZが、各々独立して、メチル、C6-10のアリール、又は5~10員のヘテロアリールであり;
ただし、X、Y又はZのうち少なくとも一つはC6-10アリール、又は5~10員のヘテロアリールであり、ここにおいて、*の立体化学がS配置のとき、Yはメチルを表し;
R4、R5、またはR6が、各々独立して、ウンデシルであり;
n、o及びpが、各々独立して、7~9の整数である、
化合物または製薬学的に許容される塩。
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例1);
(2S)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例2);
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[4-{[(3R)-3-(デカノイロキシ)テトラデカノイル]オキシ}-5-ヒドロキシ-6-(ヒドロキシメチル)-3-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)オキサン-2-イル]オキシ}プロパン酸(実施例3);
(2R)-2-({[(3R)-3-(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-(デカノイロキシ)テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例4);及び
(2S)-2-({[(3R)-3-(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-(デカノイロキシ)テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸(実施例5)。
式(1)で表される本発明の化合物は、例えば、下記の製造法1~3により製造することができる。
式(1)で表される化合物は、例えば下記の製法により製造することができる。
化合物a3は、化合物a1に、適切な縮合剤存在下、適切な溶媒中、化合物a2を反応させることにより製造される。縮合剤としては後記に例示される試薬等から適宜選択されるが、好ましくはカルボジイミド類、より好ましくは1-[3-(ジメチルアミノ)プロピル]-3-エチルカルボジイミドメチオジドが挙げられる。好ましくは縮合反応の促進剤としてN,N-ジメチル-4-アミノピリジン(DMAP)又は4-ピロリジノピリジンと共に用いられる。使用される溶媒は、後記に例示される溶媒等から適宜選択されるが、好ましくはクロロホルム、ジクロロメタンが挙げられる。反応時間は、通常、5分~48時間であり、好ましくは1時間~24時間である。反応温度は、通常、-78℃~100℃、好ましくは、0℃~50℃である。
化合物a4は、化合物a3のアミノの保護基PG1を脱保護することにより製造される。本工程はProtective Groups in Organic Synthesis(Theodora W. Greene, Peter G. M. Wuts著、John Wiley & Sons, Inc.発行、1999年)に記載されている方法等に準じて行うことができる。
化合物a6は、化合物a4に適切な縮合剤存在下、適切な溶媒中、化合物a5を反応させることにより製造される。縮合剤としては後記に例示される試薬等から適宜選択されるが、好ましくは1-エトキシカルボニル-2-エトキシ-1,2-ジヒドロキノリンが挙げられる。使用される溶媒は、後記に例示される溶媒等から適宜選択されるが、好ましくはクロロホルム、ジクロロメタンが挙げられる。反応時間は、通常、5分~48時間であり、好ましくは1時間~24時間である。反応温度は、通常、-78℃~100℃、好ましくは、0℃~50℃である。
化合物a7は、化合物a6のアミノの保護基PG2を脱保護することにより製造される。本工程はProtective Groups in Organic Synthesis(Theodora W. Greene, Peter G. M. Wuts著、John Wiley & Sons, Inc.発行、1999年)に記載されている方法等に準じて行うことができる。
化合物a9は、上記記載の工程1-3に準じた方法で化合物a7に化合物a8を反応させることにより製造される。
式(1)で表される化合物は化合物a9の保護基PG3を、PA及びPA’にO-PG4及び/又はC(O)OPG5を含む場合は、更にPG4及び/又はPG5を脱保護することにより製造される。本工程はProtective Groups in Organic Synthesis(Theodora W. Greene, Peter G. M. Wuts著、John Wiley & Sons, Inc.発行、1999年)に記載されている方法等に準じて行うことができる。
製造法1に記載される化合物a2は、式(1)の化合物においてR1が-C(O)(CH2)n-Xである場合、例えば下記の製法により製造することができる。R2が-C(O)(CH2)o-Yである場合の化合物a5、R3が-C(O)(CH2)p-Zである場合の化合物a8についても同様の製法で製造可能である。
製造法1に記載される化合物a2は式(1)の化合物においてR1が-CH2-(CH2)n-Xである場合、例えば下記の製法により製造することができる。R2が-CH2(CH2)o-Yである場合の化合物a5、R3が-CH2(CH2)p-Zである場合の化合物a8についても同様の製法で製造可能である。
出発化合物及び目的化合物の好適な塩及び医薬として許容しうる塩は、慣用の無毒性塩であり、それらとしては、有機酸塩(例えば酢酸塩、トリフルオロ酢酸塩、マレイン酸塩、フマル酸塩、クエン酸塩、酒石酸塩、メタンスルホン酸塩、ベンゼンスルホン酸塩、ギ酸塩又はpara-トルエンスルホン酸塩など)及び無機酸塩(例えば塩酸塩、臭化水素酸塩、ヨウ化水素酸塩、硫酸塩、硝酸塩又はリン酸塩など)のような酸付加塩、アミノ酸(例えばアルギニン、アスパラギン酸又はグルタミン酸など)との塩、アルカリ金属塩(例えばナトリウム塩又はカリウム塩など)及びアルカリ土類金属塩(例えばカルシウム塩又はマグネシウム塩など)などの金属塩、アンモニウム塩、又は有機塩基塩(例えばトリメチルアミン塩、トリエチルアミン塩、ピリジン塩、ピコリン塩、ジシクロヘキシルアミン塩又はN,N’-ジベンジルエチレンジアミン塩など)などの他、当業者が適宜選択することができる。
また、本発明化合物及びその製薬学的に許容される塩は、水あるいは各種溶媒との溶媒和物の形で存在することもあるが、これらの付加物も本発明に包含される。
再結晶溶媒としては例えば、メタノール、エタノールもしくは2-プロパノールなどのアルコール系溶媒、ジエチルエーテルなどのエーテル系溶媒、酢酸エチルなどのエステル系溶媒、ベンゼンもしくはトルエンなどの芳香族炭化水素系溶媒、アセトンなどのケトン系溶媒、ジクロロメタンもしくはクロロホルムなどのハロゲン系溶媒、ヘキサンなどの炭化水素系溶媒、ジメチルホルムアミドもしくはアセトニトリルなどの非プロトン系溶媒、水、又はこれらの混合溶媒などを用いることができる。その他の精製方法としては、実験化学講座(日本化学会編、丸善)1巻などに記載された方法などを用いることができる。また、本発明化合物の分子構造の決定は、それぞれの原料化合物に由来する構造を参照して、核磁気共鳴法、赤外吸収法、円二色性スペクトル分析法などの分光学的手法、及び質量分析法により容易に行える。
すなわち、本発明の化合物又はその薬学上許容される塩は、抗原特異的抗体、詳しくは抗原特異的IgG、さらに詳しくはTh1型抗原特異的IgG(例えばIgG2c)を誘導又は亢進する活性を有する。
また、本発明の化合物又はその製薬学的に許容される塩は、細胞傷害性T細胞(CTL)を増加させる活性を有する。または、本発明の化合物又はその製薬学的に許容される塩は、哺乳動物におけるCTLを誘導する活性、もしくは哺乳動物におけるCTL誘導を増強する活性を有する。
また、本発明の化合物又はその製薬学的に許容される塩は、CD4陽性(すなわち、MHC class II拘束性)及び/又はCD8陽性(すなわち、MHC Class I拘束性)T細胞を増加させる活性を有する。
また、本発明の化合物又はその製薬学的に許容される塩は、抗原特異的なT細胞を増加させる活性を有する。
また、本発明の化合物又はその製薬学的に許容される塩は、メモリーT細胞、詳しくはCD8陽性エフェクターメモリーT細胞を増加させる活性を有する。
また、本発明の化合物又はその製薬学的に許容される塩は、哺乳動物に投与した場合、CTLを増加させる作用が、同モル数のリン酸構造を含むTLR4アゴニスト活性を有するアジュバント化合物を投与した場合と同程度であるという特徴を有する。
また、本発明の化合物またはその製薬学的に許容される塩は、免疫担当細胞を活性化させる活性を有する。
水性溶液製剤もしくは水性懸濁液剤としては、例えば抗原(腫瘍抗原または病原体由来抗原)、及び/又は式(1)で表される化合物又はその薬学上許容される塩を、水に溶解又は分散させた製剤が挙げられる。
油性溶液製剤もしくは油性懸濁液剤としては、例えば抗原(腫瘍抗原または病原体由来抗原)、及び/又は式(1)で表される化合物又はその薬学上許容される塩を、油性成分に溶解又は分散させた製剤が挙げられる。
脂質製剤としては、例えば抗原(腫瘍抗原または病原体由来抗原)、及び/又は式(1)で表される化合物又はその薬学上許容される塩を含有するリポソーム製剤が挙げられる。
エマルション製剤としては、例えば抗原(腫瘍抗原または病原体由来抗原)、及び/又は式(1)で表される化合物又はその薬学上許容される塩を含有する水性の溶液及び油状組成物を含む製剤が挙げられる。
本発明の水性溶液製剤もしくは水性懸濁液剤に使用される添加剤としては、例えば精製水、注射用水、緩衝剤、pH調節剤、安定化剤、等張化剤、可溶化剤又は溶解補助剤等が挙げられる。
本発明の油性溶液製剤もしくは油性懸濁液剤に使用される添加剤としては、例えば緩衝剤、pH調節剤、安定化剤、等張化剤、動植物性油脂、炭化水素類、脂肪酸、脂肪酸エステル類、可溶化剤又は溶解補助剤等が挙げられる。
本発明の油中水型エマルション製剤は、公知の方法により水相及び油相を乳化して製造することができる。本発明の油中水型エマルション製剤において、抗原(腫瘍抗原または病原体由来抗原)、及び/又は式(1)で表される化合物又はその薬学上許容される塩は、エマルション中の油相及び水相のいずれか一方又はその両方に含有しうる。
本発明の化合物もしくはその薬学上許容される塩、及び腫瘍特異的免疫反応を増強させる物質(腫瘍由来抗原ともいう)または病原体特異的免疫反応を増強させる物質(病原体由来抗原ともいう)を含む医薬組成物も、本発明の一態様である。当該腫瘍抗原または病原体由来抗原としては、特に限定はないが、腫瘍由来抗原タンパク質、病原体由来抗原タンパク質、該腫瘍由来抗原タンパク質に由来する腫瘍由来抗原ペプチド、又は該病原体由来抗原タンパク質に由来する病原体由来抗原ペプチド(部分ペプチド)、さらにこれらと担体との複合体が挙げられる。
a)式(1)で示される化合物、又はその薬学上許容し得る塩、もしくは式(1)で示される化合物又はその薬学上許容し得る塩を含有する医薬組成物;
b)腫瘍由来抗原または病原体由来抗原を含有する医薬組成物。
本発明の一態様として、以下を含有するキットを提供する:
a)式(1)で示される化合物、又はその薬学上許容し得る塩、もしくは式(1)で示される化合物又はその薬学上許容し得る塩を含有する医薬組成物;
b)病原体由来抗原を含有する医薬組成物。
ここで、抗原としては、ワクチンの有効成分として用いられ得る抗原であれば特に限定はないが、上述の抗原タンパク質又は該抗原タンパク質に由来する抗原ペプチド(部分ペプチド)等、さらにこれらと担体との複合体等が挙げられる。
また、本発明の一態様として、感染症の処置のためのワクチンの製造における、ワクチンアジュバントとしての、上で定義した式(I)で示される化合物、又はその薬学上許容し得る塩の使用を提供する。
また、本発明の一態様として、上で定義した式(I)で示される化合物、又はその薬学上許容し得る塩を、病原体由来抗原とともに患者に投与する工程を含む、感染症の治療、進行防止又は予防方法を提供する。
TBS:tert-ブチルジメチルシリル基
Bn:ベンジル基
Fmoc:9-フルオレニルメチルオキシカルボニル
DBU:ジアザビシクロウンデセン
Boc:tert-ブトキシカルボニル
Alko:p-アルコキシベンジルアルコール
PEG:ポリエチレングリコール
tBu:tert-ブチル
HBTU:O-(ベンゾトリアゾール-1-イル)-N,N,N’,N’-テトラメチルウロニウムヘキサフルオロホスファート
DIPEA:N,N-ジイソプロピルエチルアミン
DMF:N,N-ジメチルホルムアミド
TFA:トリフルオロ酢酸
TIS:トリイソプロピルシラン
THF:テトラヒドロフラン
TBDPS:tert-ブチルジフェニルシリル基
LCMS条件A
MS検出器:LCMS-IT-TOF
HPLC:Shimadzu Nexera X2 LC 30AD
カラム:Kinetex 1.7μ C18 100A New column 50×2.1mm
流速:1.2ml/min
測定波長:254/220nm
移動相:A液;0.1%ギ酸水溶液
B液;アセトニトリル
タイムプログラム:
ステップ 時間(分)
1 0.01-1.40 A液:B液=90:10~5:95
2 1.40-1.60 A液:B液=5:95
3 1.61-2.00 A液:B液=99:1
MS検出器:ACQUITY(登録商標)SQdetecter (Waters社)
HPLC:ACQUITY(登録商標)system
カラム:Waters ACQUITY UPLC(登録商標)BEH C18(1.7μm,2.1mm×30mm)
流速:0.8ml/min
測定波長:254/220nm
移動相:A液:0.06%ギ酸/アセトニトリル
B液:0.06%ギ酸水溶液
タイムプログラム:0.0-1.30 A液:B液=2:98~96:4
カラム温度:25℃
MS検出器:LCMS-IT-TOF
HPLC:Shimadzu Nexera X2 LC 30AD
カラム:なし
流速:1.2ml/min
測定波長:254/220nm
移動相:A液;0.1%ギ酸水溶液
B液;アセトニトリル
タイムプログラム:
ステップ 時間(分)
1 0.01-1.40 A液:B液=90:10~5:95
2 1.40-1.60 A液:B液=5:95
3 1.61-2.00 A液:B液=99:1
2-(4-ブロモフェニル)-2-オキソエチル (3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノエート
1H-NMR (400 MHz, CDCl3): 7.73 (2H, dt, J = 9.0, 2.1 Hz), 7.60 (2H, dt, J = 9.0, 2.1 Hz), 7.27-7.22 (2H, m), 7.17-7.12 (3H, m), 5.29-5.23 (3H, m), 2.77-2.66 (2H, m), 2.57 (2H, t, J = 7.9 Hz), 2.28 (2H, t, J = 7.9 Hz), 1.70-1.50 (6H, m), 1.35-1.20 (26H, m), 0.86 (3H, dd, J = 7.9, 5.5 Hz).
(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカン酸
1H-NMR (400 MHz, CDCl3): 7.28-7.23 (2H, m), 7.16-7.11 (3H, m), 5.22-5.15 (1H, m), 2.64-2.52 (4H, m), 2.25 (2H, t, J = 7.6 Hz), 1.60-1.50 (6H, m), 1.32-1.20 (26H, m), 0.86 (3H, t, J = 7.0 Hz).
(2R)-3-(ベンジロキシ)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-オキソプロピル 6-O-[tert-ブチル(ジメチル)シリル]-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-2-デオキシ-3-O-{(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}ヘキソピラノシド
(2R)-3-{[6-({[tert-ブチル(ジメチル)シリル]オキシ}メチル)-4,5-ジヒドロキシ-3-{[(2,2,2-トリクロロエトキシ)カルボニル]アミノ}オキサン-2-イル]オキシ}-2-{[(2,2,2-トリクロロエトキシ)カルボニル]アミノ}プロパン酸ベンジル(464mg)、参考例2の化合物(853mg)、4-ピロリジノピリジン(14mg)をジクロロメタン(40mL)に溶解させた後、1-[3-(ジメチルアミノ)プロピル]-3-エチルカルボジイミドメチオジド(550mg)を0度で加えた。反応溶液を室温で18時間撹拌した後、水/クロロホルムで抽出した。有機層を無水硫酸マグネシウムで乾燥させ、濃縮した残渣をシリカゲルカラムクロマトグラフィー(溶出溶媒;ヘキサン:酢酸エチル)で精製し掲題の化合物Q1(1.62g)を得た。
1H-NMR (400 MHz, CDCl3): 7.30 (5H, m), 7.24-7.15 (2H, m), 7.12-7.06 (3H, m), 5.95 (1H, d, J = 9.8 Hz), 5.26 (1H, d, J = 12.2 Hz), 5.12-5.02 (1H, m), 4.97 (1H, d, J = 11.7 Hz), 4.84-4.60 (5H, m), 4.50-4.40 (2H, m), 4.00-3.87 (2H, m), 3.78 (2H, qd, J = 10.8, 4.6 Hz), 3.60-3.36 (3H, m), 3.20-3.10 (1H, m), 2.57-2.42 (5H, m), 2.20 (2H, t, J = 7.6 Hz), 1.56-1.40 (6H, m), 1.39-1.20 (26H, m), 0.83-0.75 (12H, m), 0.00 (6H, s).
化合物Q1(1.62g)を酢酸(18mL)に溶解させ、亜鉛粉末(2.79g)を加えた後室温にて2時間撹拌した。反応液をセライトでろ過した後、炭酸水素ナトリウム水溶液で中和しクロロホルムで抽出した。有機層を無水硫酸マグネシウムで乾燥させ、ろ過、濃縮した。得られた残渣(1.15g)と(3R)-3-(デカノイロキシ)テトラデカン酸(1.10g)をジクロロメタン(70mL)に溶解させた後、1-エトキシカルボニル-2-エトキシ-1,2-ジヒドロキノリン(746mg)を加え室温にて16時間撹拌した。反応液をシリカゲルカラムクロマトグラフィー(溶出溶媒;ヘキサン:酢酸エチル)で精製し、掲題の化合物(1.38g)を得た。
1H-NMR (400 MHz, CDCl3):7.35-7.32 (5H, m), 7.21-7.17 (2H, m), 7.12-7.07 (3H, m), 6.65 (1H, d, J = 8.5 Hz), 5.44 (1H, d, J = 8.5 Hz), 5.22-4.94 (5H, m), 4.69-4.61 (2H, m), 3.91-3.73 (5H, m), 3.65 (1H, q, J = 9.5 Hz), 3.49 (1H, t, J = 11.6 Hz), 3.39 (1H, d, J = 2.4 Hz), 3.11-3.06 (1H, m), 2.54-2.16 (14H, m), 1.51 (14H, s), 1.20 (86H, m), 0.82-0.78 (24H, m), 0.00 (6H, s).
(2R)-3-(ベンジロキシ)-3-オキソ-2-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)プロピル 6-O-[tert-ブチル(ジメチル)シリル]-3-O-[(3R)-3-(デカノイロキシ)テトラデカノイル]-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-2-デオキシヘキソピラノシド
参考例3のa工程と同様に反応、処理して掲題の化合物Q2を得た。
LCMS(条件A):1271.5[M+Na+]、1.26min
化合物Q2(220mg)を酢酸(2mL)に溶解させ、粉末亜鉛(346mg)を加えて室温にて2.5時間撹拌した。反応溶液をセライトでろ過し、水/酢酸エチルで抽出した。有機層を無水硫酸マグネシウムで乾燥させ、濃縮して得られた残渣をシリカゲルカラムクロマトグラフィー(溶出溶媒;ヘキサン:酢酸エチル)で精製することにより掲題の化合物Q3(114mg)を得た。
1H-NMR (CDCl3) δ: 7.73 (2H, d, J = 7.9 Hz), 7.57 (2H, d, J = 6.7 Hz), 7.38-7.25 (9H, m), 5.88 (1H, d, J = 8.5 Hz), 5.22-5.08 (3H, m), 4.73 (1H, t, J = 9.4 Hz), 4.54 (1H, d, J = 8.5 Hz), 4.40 (1H, dd, J = 10.4, 6.7 Hz), 4.29 (1H, dd, J = 10.7, 7.6 Hz), 4.20 (1H, t, J = 7.3 Hz), 4.10-3.95 (3H, m), 3.90-3.74 (2H, m), 3.55 (1H, t, J = 9.1 Hz), 3.40-3.20 (2H, m), 2.71-2.58 (3H, m), 2.25 (2H, t, J = 7.3 Hz), 1.65-1.30 (6H, m), 1.30-1.10 (30H, m), 0.86-0.80 (15H, m), 0.01 (6H, d, J = 3.0 Hz).
化合物Q3(114mg)、(3R)-3-(デカノイロキシ)テトラデカン酸(46.6mg)をジクロロメタン(3mL)に溶解させた後、1-エトキシカルボニル-2-エトキシ-1,2-ジヒドロキノリン(31.5mg)を加え室温にて16時間撹拌した。反応液をシリカゲルカラムクロマトグラフィー(溶出溶媒;ヘキサン:酢酸エチル)で精製し、化合物Q4(107mg)を得た。
1H-NMR (400 MHz, CDCl3):7.70 (2H, d, J = 7.9 Hz), 7.59 (2H, d, J = 7.3 Hz), 7.36-7.21 (9H, m), 5.94 (1H, d, J = 9.1 Hz), 5.49 (1H, d, J = 8.5 Hz), 5.25 (1H, d, J = 12.2 Hz), 5.15-5.01 (3H, m), 4.74 (1H, t, J = 10.1 Hz), 4.43 (1H, d, J = 9.1 Hz), 4.33 (1H, dd, J = 10.4, 7.3 Hz), 4.25 (1H, t, J = 8.8 Hz), 4.18 (1H, t, J = 7.3 Hz), 4.03-3.92 (3H, m), 3.83-3.69 (3H, m), 3.53 (1H, t, J = 9.1 Hz), 3.41 (1H, d, J = 2.4 Hz), 3.18-3.10 (1H, m), 2.57-2.37 (3H, m), 2.26-2.21 (5H, m), 1.60-1.40 (8H, m), 1.30-1.10 (60H, m), 0.86-0.79 (21H, m), 0.00 (6H, d, J = 2.4 Hz).
化合物Q4(107mg)のジクロロメタン(3mL)溶液に対し、DBU(4.48mg)のジクロロメタン溶液(0.1mL)を加え、室温にて30分撹拌した。その後、反応溶液を直接シリカゲル上にのせ、シリカゲルカラムクロマトグラフィー(溶出溶媒;クロロホルム:メタノール)で精製することにより化合物Q5(89mg)を得た。
1H-NMR (400 MHz, CDCl3):7.34-7.27 (5H, m), 5.68 (1H, d, J = 9.2 Hz), 5.16 (1H, d, J = 12.2 Hz), 5.10-5.01 (3H, m), 4.75 (1H, dd, J = 11.0, 9.2 Hz), 4.16 (1H, d, J = 7.9 Hz), 3.98 (1H, dd, J = 9.8, 3.1 Hz), 3.82-3.38 (7H, m), 3.20-3.15 (1H, m), 2.54-2.34 (3H, m), 2.24-2.18 (5H, m), 1.60-1.40 (8H, m), 1.28-1.10 (60H, m), 0.83-0.76 (21H, m), 0.00 (6H, d, J = 2.4 Hz).
参考例Q5の化合物(89mg)と参考例2の化合物(36.5mg)のジクロロメタン(3mL)溶液に対し、1-エトキシカルボニル-2-エトキシ-1,2-ジヒドロキノリン(21.4mg)を加え室温にて18時間撹拌した。反応溶液を濃縮して得られた残渣をシリカゲルカラムクロマトグラフィー(溶出溶媒;ヘキサン:酢酸エチル)で精製することにより参考例4の化合物(97mg)を得た。
1H-NMR (400 MHz, CDCl3):7.37-7.17 (7H, m), 7.12-7.07 (3H, m), 6.68 (1H, d, J = 8.5 Hz), 5.45 (1H, d, J = 8.5 Hz), 5.22-4.94 (5H, m), 4.70-4.60 (2H, m), 3.90-3.70 (5H, m), 3.65 (1H, td, J = 9.3, 7.3 Hz), 3.49 (1H, t, J = 9.5 Hz), 3.41 (1H, d, J = 2.4 Hz), 3.12-3.07 (1H, m), 2.53-2.36 (7H, m), 2.24-2.15 (7H, m), 1.60-1.40 (14H, m), 1.30-1.10 (86H, d, J = 9.8 Hz), 0.82-0.78 (24H, m), 0.00 (6H, s).
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸
1H-NMR (400 MHz, CDCl3/CD3OD(30:1)):7.19 (2H, d, J = 7.6 Hz), 7.11-7.08 (3 H, m), 5.18-5.14 (1H, m), 5.04 (2H, s), 4.83 (1H, t, J = 9.1 Hz), 4.51 (1H, s), 4.32 (1H, d, J = 8.5 Hz), 3.95-3.60 (4H, m), 3.49 (1H, t, J = 9.4 Hz), 3.35-3.26 (2H, m), 2.54-2.37 (6H, m), 2.26-2.18 (8H, m), 1.51 (14H, s), 1.18 (86H, s), 0.81 (15H, t, J = 6.7 Hz).
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)-5-(ホスホノオキシ)オキサン-2-イル]オキシ}プロパン酸
参考例3の化合物(400mg)のジクロロメタン(8mL)溶液に、ジベンジル N,N-ジイソプロピルホスホロアミダイト(231mg)と4,5-ジシアノイミダゾール(79mg)を加え、室温で18時間撹拌した。その後、反応溶液に3-クロロ過安息香酸(190mg)を加え、0度で1時間撹拌した。炭酸水素ナトリウム水溶液を加えて15分室温にて撹拌した後に、クロロホルムで抽出した。有機層を無水硫酸マグネシウムで乾燥させ、濃縮して得られた残渣をシリカゲルカラムクロマトグラフィー(溶出溶媒;ヘキサン:酢酸エチル)で精製し、化合物Q6(365mg)を得た。
1H-NMR (400 MHz, CDCl3):7.43-7.24 (17H, m), 7.19-7.13 (3H, m), 6.79 (1H, d, J = 8.2 Hz), 5.81 (1H, d, J = 8.2 Hz), 5.29-5.05 (6H, m), 4.96 (4H, dd, J = 18.3, 7.8 Hz), 4.75-4.68 (1H, m), 4.31-4.25 (2H, m), 4.00-3.85 (3H, m), 3.68 (1H, dd, J = 11.4, 5.5 Hz), 3.55 (1H, dt, J = 14.5, 5.6 Hz), 3.31-3.26 (1H, m), 2.61-2.18 (14H, m), 1.70-1.50 (14H, m), 1.35-1.18 (86H, dd, J = 34.3, 27.4 Hz), 0.88 (15H, td, J = 6.7, 2.4 Hz), 0.85 (9H, s), 0.00 (6H, d, J = 5.5 Hz).
化合物Q6(365mg)のTHF(20mL)溶液に10%パラジウム炭素(248mg)と2mol/L塩酸(0.5mL)を加え水素雰囲気下(4気圧)室温にて8時間撹拌した。その後、反応液をセライトでろ過して濃縮して得られた残渣をシリカゲルカラムクロマトグラフィー(溶出溶媒;クロロホルム:メタノール(メタノールには水2.5%・トリエチルアミン2.5%を添加したものを用いた))で精製し、表題の化合物(140mg)を得た。
1H-NMR (400 MHz, CDCl3/CD3OD(30:1)):7.19 (2H, d, J = 7.3 Hz), 7.11-7.07 (3H, m), 5.22-4.99 (4H, m), 4.61-4.52 (1H, m), 4.42-4.32 (1H, m), 4.21-4.10 (1H, m), 3.95-3.80 (2H, m), 3.80-3.60 (2H, m), 3.34-3.20 (2H, m), 2.97 (4H, q, J = 7.3 Hz), 2.60-2.30 (6H, m), 2.30-2.10 (8H, m), 1.60-1.40 (14H, m), 1.30-1.10 (86H, m), 0.80 (15H, t, J = 6.7 Hz).
ヒトTLR4レポータージーンアッセイ
HEK-BlueTM hTLR4細胞株(Invivogen社)は、NF-κB応答エレメントの転写制御下で、ヒトTLR4、MD2、CD14と、分泌型アルカリフォスファターゼ(SEAP)レポーター遺伝子を発現する安定なコトランスフェクト細胞株である。この細胞株でのTLR4発現は、RT-PCR、フローサイトメトリーにより試験済みである。抗生物質HEK-BlueTM Selectionを使用して、安定に発現する形質転換体を選択した。TLRシグナル伝達はNF-κBの転位を導き、プロモーターの活性化はSEAP遺伝子の発現をもたらす。この細胞を0.1%(v/v)DMSO存在下で37℃にて実施例及び参考例で合成された化合物と16~20時間インキュベーションした後、生成したSEAPのレベルを測定することにより、TLR4特異的な活性化を評価した。本発明化合物のヒトTLR4活性化の程度を、ヒトTLR4レポータージーンアッセイを用いて評価し、リポ多糖(LPS)によって誘導されたSEAPの最大レベルの半分をもたらす化合物の濃度(EC50)とした。
マウスTLR4レポータージーンアッセイ
HEK-BlueTM mTLR4細胞株(Invivogen社)は、NF-κB応答エレメントの転写制御下で、マウスTLR4、MD2、CD14と、分泌型SEAPレポーター遺伝子を発現する安定なコトランスフェクト細胞株である。この細胞株でのTLR4発現は、RT-PCR、フローサイトメトリーにより試験済みである。抗生物質HEK-BlueTM Selectionを使用して、安定に発現する形質転換体を選択した。TLRシグナル伝達はNF-κBの転位を導き、プロモーターの活性化はSEAP遺伝子の発現をもたらす。この細胞を0.1%(v/v)DMSO存在下で37℃にて実施例及び参考例で合成された化合物と16~20時間インキュベーションした後、生成したSEAPのレベルを測定することにより、TLR4特異的な活性化を評価した。本発明化合物のマウスTLR4活性化の程度を、マウスTLR4レポータージーンアッセイを用いて評価し、LPSによって誘導されたSEAPの最大レベルの半分をもたらす化合物の濃度(EC50)とした。
1,2-ジミリストイル-sn-グリセロ-3-ホスホコリン35.45mg、卵黄ホスファチジルグリセロール24.45mg、表7に記載の化合物6mgをt-ブチルアルコールに溶解した後、凍結乾燥し、リン酸緩衝生理食塩水3mLを加えた。この液を、約65℃に加温したエクストルーダー(Mini-Extruder、Avanti Polar Lipids製)を用い、0.1μmのポリカーボネイトメンブランを通過させ、リポソーム製剤とした。調製量は必要に応じて増減した。なお、参考例17の製剤についてLCMS条件Cにて行ったところ、参考例10の化合物は検出されなかった。参考例10の化合物はリポソーム化されておらず、エクストルーダーのメンブランにてトラップされたものと考えられた。
上記リポソームを精製水で10倍希釈し、動的光散乱法(ZETASIZER Nano-ZS、Malvern製)により、平均粒子径、多分散指数及びゼータ電位を測定した。また、実施例6、7及び参考例16の製剤について高速液体クロマトグラフィ(HPLC)により、定量を行った。
HPLC条件
検出器:UV(205nm)
HPLC:Shimadzu LC 20AD
カラム:XSelect CSH Phenyl-Hexyl 2.5μm 75×4.6mm
流速:0.8ml/min
移動相:A液;0.1%トリフルオロ酢酸水溶液
B液;2-プロパノール
タイムプログラム:
ステップ 時間(分)
1 0.0-7.0 A液:B液=20:80
2 7.0-7.5 A液:B液=20:80~5:95
3 7.5-11.0 A液:B液=5:95
4 11.0-11.1 A液:B液=5:95~20:80
5 11.1-15.0 A液:B液=20:80
結果を表7に示した。
7週齢のC57BL/6雄性マウスに、抗原としてのオボアルブミン(OVA)(2 mg/mL)と、実施例6、実施例7、又は参考例16で調製した製剤(実施例1、実施例2または参考例9の化合物を0.2または2 mg/mL含有する)の等量混合液(100μL/マウス)を、腓腹筋に筋肉内投与し初回免疫とした。さらに2週間後に、等量の同混合液を腓腹筋に筋肉内投与し追加免疫とした。追加免疫から1週間後、イソフルラン吸入麻酔維持下において心臓採血を行い、遠心分離により血清を回収した。血清中のOVA特異的IgG2c値を、次のELISA法によって定量した。すなわち、96wellプレートにOVA溶液(SIGMA)を添加した後、1%スキムミルク(Wako)にてブロッキングを行い、リン酸緩衝液を用いて希釈した血清サンプルを添加後、二次抗体であるヤギ抗マウスIgG2c(Southern Bio)を添加し、SureBlue(登録商標)TMB Micrewell Peroxidase Substrate(KPL)添加後、酵素反応の生成物をマイクロプレートリーダーにて測定し定量した。結果を図1および図2に示す。
実施例1、実施例2および参考例9において、陰性対照群と比較して有意に強いOVA特異的IgG2c誘導を示した。
試験例3で調製したオボアルブミン(OVA)(2 mg/mL)と実施例6、実施例7、又は参考例16で調製した製剤(実施例1、実施例2または参考例9の化合物を0.2または2 mg/mL含有する)の等量混合液(100μL/マウス)をマウスに投与して、その脾臓細胞を調製し、OVAとブレフェルジンA(eBioscience)を添加後一晩培養した。細胞を回収し、APC標識抗マウスCD3e抗体(invitrogen)、PerCP標識抗マウスCD4抗体(BioLegend)およびFixable Viability Dye eFluorTM520(invitorgen)で染色後、Fixation/Permeabilization buffer(invitrogen)で固定した。細胞をPermeabilization buffer(invitrogen)処置後、抗体カクテルBV421標識抗IFN-γ抗体(BioLegend)、PE-Cy7標識抗IL-2抗体(eBioscience)およびPE標識TNF-α(BioLegend)で染色した。FACS Cant II(BD Biosciences)およびFLOWJOソフトウェア(TreeStar)を用いてデータ取り込みおよび解析を行った。結果を図3および図4に示す。
また別に、上記脾臓細胞を、V450標識抗マウスCD3e抗体(invitrogen)、Alexa Fluor(登録商標)647標識抗マウスCD8抗体(MBL)、PE標識H-2Kb OVA Tetramer-SIINFEKL(MBL)およびFixable Viability dye eFluor 520(invitrogen)で染色した。FACS Cant II(BD Biosciences)およびFLOWJOソフトウェア(TreeStar)を用いてデータ取り込みおよび解析を行った。結果を図5および図6に示す。
更に別に、上記脾臓細胞を、V450標識抗マウスCD3e抗体(invitrogen)、Alexa Fluor(登録商標)647標識抗マウスCD8抗体(MBL)、PE-Cy7標識抗マウスCD44抗体(invitrogen)、PerCP-Cy5.5標識抗マウスCD62L抗体(invitrogen)およびFixable Viability dye eFluor 520(invitrogen)で染色した。FACS Cant II(BD Biosciences)およびFLOWJOソフトウェア(TreeStar)を用いてデータ取り込みおよび解析を行った。結果を図7および図8に示す。
実施例1、実施例2および参考例9の化合物は、OVA特異的1型ヘルパーT細胞、特にOVA特異的multifunctional CD4陽性Tリンパ球の割合や、MHC拘束性OVA特異的CD8陽性Tリンパ球(図5および図6のOVAテトラマー陽性CD8T細胞)の割合、およびCD8陽性エフェクターメモリーTリンパ球の割合を陰性対照群と比較して有意に増加させた。
Claims (22)
- 式(1):
A及びA’は各々独立して、水素、ヒドロキシ又は-(CH2)m-COOHを表し、ただし、A又はA’の少なくとも1つは-(CH2)m-COOHを表し、
R1は-C(O)(CH2)n-X又は-CH2-(CH2)n-Xを表し、
R2は-C(O)(CH2)o-Y又は-CH2-(CH2)o-Yを表し、
R3は-C(O)(CH2)p-Z又は-CH2-(CH2)p-Zを表し、
X、Y、及びZは各々独立して、メチル、C6-10アリール(該C6-10アリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~5個の置換基で置換されていてもよい)又は5~10員のヘテロアリール(該5~10員のヘテロアリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~4個の置換基で置換されていてもよい)を表し、ただし、X、Y又はZのうち少なくとも一つはC6-10アリール(該C6-10アリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~5個の置換基で置換されていてもよい)又は5~10員のヘテロアリール(該5~10員のヘテロアリールは、ヒドロキシ、C1-6アルキル、ハロゲン、シアノ、及びC1-6アルコキシから独立して選択される1~4個の置換基で置換されていてもよい)を表し、
ここにおいて、Aが-COOHであり*の立体化学がS配置のとき、Yはメチルを表し、
R4、R5、及びR6は各々独立して、C10-20アルキルを表し、
mは各々独立して0~6の整数を表し、
n、o、及びpは各々独立して5~20の整数を表す]で示される化合物又はその製薬学的に許容される塩。 - mが0である、請求項1に記載の化合物又はその製薬学的に許容される塩。
- R1が-C(O)(CH2)n-Xであり、R2が-C(O)(CH2)o-Yであり、R3が-C(O)(CH2)p-Zである、請求項1又は2に記載の化合物又はその製薬学的に許容される塩。
- AがCOOHである、請求項1~3のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
- AがCOOHであり、A’がヒドロキシである、請求項1~4のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
- R4、R5、及びR6が各々独立して、C10-12アルキルである、請求項1~5のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
- 式(4)又は式(5):
R1は-C(O)(CH2)n-Xを表し、
R2は-C(O)(CH2)o-Yを表し、
R3は-C(O)(CH2)p-Zを表し、
R2’は-C(O)(CH2)o-CH3を表し、
X、Y、及びZは各々独立して、メチル、C6-10アリール又は5~10員のヘテロアリールを表し、ただし、式(4)においては、X、Y、又はZのうち少なくとも一つはC6-10アリール又は5~10員のヘテロアリールを表し、式(5)においては、X又はZの少なくとも一つはC6-10アリール又は5~10員のヘテロアリールを表し、
n、o、及びpは各々独立して7~9の整数を表す]で示される、請求項1に記載の化合物又はその製薬学的に許容される塩。 - X、Y、及びZが各々独立して、メチル又はフェニルであり、ただし、X、Y、又はZのうち少なくとも1つはフェニルであり、ここにおいて、Aが-COOH であり*の立体化学がS配置のときのとき 、Yはメチルを表す、請求項1~9のいずれか一項に記載の化合物又はその製薬学的に許容される塩。
- 以下の化合物群から選択される、請求項1に記載の化合物又はその製薬学的に許容される塩:
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸、
(2S)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸、
(2R)-2-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-3-{[4-{[(3R)-3-(デカノイロキシ)テトラデカノイル]オキシ}-5-ヒドロキシ-6-(ヒドロキシメチル)-3-({(3R)-3-[(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)オキサン-2-イル]オキシ}プロパン酸、
(2R)-2-({[(3R)-3-(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-(デカノイロキシ)テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸、及び
(2S)-2-({[(3R)-3-(9-フェニルノナノイル)オキシ]テトラデカノイル}アミノ)-3-{[3-{[(3R)-3-(デカノイロキシ)テトラデカノイル]アミノ}-5-ヒドロキシ-6-(ヒドロキシメチル)-4-({(3R)-3-(デカノイロキシ)テトラデカノイル}オキシ)オキサン-2-イル]オキシ}プロパン酸。 - 請求項1~11のいずれか一項に記載の化合物又はその製薬学的に許容される塩を含有する医薬組成物。
- 脂質製剤である、請求項12に記載の医薬組成物。
- 脂質製剤が、リン脂質を含むリポソーム製剤である、請求項12又は13に記載の医薬組成物。
- リン脂質が、1,2-ジミリストイル-sn-グリセロ-3-ホスホコリン及び卵黄ホスファチジルグリセロールである、請求項14に記載の医薬組成物。
- 無機酸、無機酸塩、有機酸、有機酸塩、糖類、緩衝剤、酸化防止剤、及びポリマー類からなる群から選択される1以上の添加物を含むリポソーム製剤である、請求項14または15に記載の医薬組成物。
- 更に抗原を含有する、請求項12~16のいずれか一項に記載の医薬組成物。
- 抗原が病原体由来抗原である、請求項17に記載の医薬組成物。
- 請求項1~11のいずれかに記載の化合物又はその製薬学的に許容される塩を含む、ワクチンアジュバント。
- 感染症ワクチンのアジュバントである、請求項19に記載のワクチンアジュバント。
- a)請求項1の式(1)で示される化合物又はその薬学上許容し得る塩、もしくは式(1)で示される化合物又はその薬学上許容し得る塩を含有する医薬組成物;および
b)抗原を含有する医薬組成物
を含有するキット。 - 抗原が、病原体由来抗原である、請求項21に記載のキット。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3187828A CA3187828A1 (en) | 2020-06-22 | 2021-06-21 | Adjuvant with tlr4 agonist activity |
CN202180051288.3A CN116056721A (zh) | 2020-06-22 | 2021-06-21 | 具有tlr4激动剂活性的佐剂 |
KR1020237001883A KR20230026438A (ko) | 2020-06-22 | 2021-06-21 | Tlr4 작동 활성을 갖는 아쥬반트 |
JP2022531976A JPWO2021261444A1 (ja) | 2020-06-22 | 2021-06-21 | |
EP21829834.7A EP4169527A1 (en) | 2020-06-22 | 2021-06-21 | Adjuvant with tlr4 agonist activity |
PE2022002961A PE20230463A1 (es) | 2020-06-22 | 2021-06-21 | Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4) |
BR112022025969A BR112022025969A2 (pt) | 2020-06-22 | 2021-06-21 | Adjuvante com atividade agonista de tlr4 |
IL299253A IL299253A (en) | 2020-06-22 | 2021-06-21 | Helps with TLR4 agonist activity |
MX2022016181A MX2022016181A (es) | 2020-06-22 | 2021-06-21 | Adyuvante con actividad agonista del receptor tipo toll 4 (tlr4). |
US18/011,586 US20230287027A1 (en) | 2020-06-22 | 2021-06-21 | Adjuvant with tlr4 agonist activity |
AU2021295796A AU2021295796A1 (en) | 2020-06-22 | 2021-06-21 | Adjuvant with TLR4 agonist activity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020-107194 | 2020-06-22 | ||
JP2020107194 | 2020-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021261444A1 true WO2021261444A1 (ja) | 2021-12-30 |
Family
ID=79281148
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/023402 WO2021261444A1 (ja) | 2020-06-22 | 2021-06-21 | Tlr4作動活性を有するアジュバント |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230287027A1 (ja) |
EP (1) | EP4169527A1 (ja) |
JP (1) | JPWO2021261444A1 (ja) |
KR (1) | KR20230026438A (ja) |
CN (1) | CN116056721A (ja) |
AU (1) | AU2021295796A1 (ja) |
BR (1) | BR112022025969A2 (ja) |
CA (1) | CA3187828A1 (ja) |
CL (1) | CL2022003689A1 (ja) |
IL (1) | IL299253A (ja) |
MX (1) | MX2022016181A (ja) |
PE (1) | PE20230463A1 (ja) |
WO (1) | WO2021261444A1 (ja) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050399A1 (en) | 1997-05-08 | 1998-11-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
WO2001034617A2 (en) | 1999-11-12 | 2001-05-17 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
WO2001036433A2 (en) | 1999-11-15 | 2001-05-25 | Biomira, Inc. | Synthetic lipid-a analogs and uses thereof |
WO2004062599A2 (en) | 2003-01-06 | 2004-07-29 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US20080188566A1 (en) | 2007-02-01 | 2008-08-07 | Pan Thera Biopharma,Llc | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning |
WO2016109880A1 (en) * | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
WO2019157509A1 (en) * | 2018-02-12 | 2019-08-15 | Inimmune Corporation | Toll-like receptor ligands |
-
2021
- 2021-06-21 WO PCT/JP2021/023402 patent/WO2021261444A1/ja active Application Filing
- 2021-06-21 BR BR112022025969A patent/BR112022025969A2/pt unknown
- 2021-06-21 EP EP21829834.7A patent/EP4169527A1/en active Pending
- 2021-06-21 CN CN202180051288.3A patent/CN116056721A/zh active Pending
- 2021-06-21 IL IL299253A patent/IL299253A/en unknown
- 2021-06-21 MX MX2022016181A patent/MX2022016181A/es unknown
- 2021-06-21 CA CA3187828A patent/CA3187828A1/en active Pending
- 2021-06-21 KR KR1020237001883A patent/KR20230026438A/ko unknown
- 2021-06-21 US US18/011,586 patent/US20230287027A1/en active Pending
- 2021-06-21 PE PE2022002961A patent/PE20230463A1/es unknown
- 2021-06-21 AU AU2021295796A patent/AU2021295796A1/en active Pending
- 2021-06-21 JP JP2022531976A patent/JPWO2021261444A1/ja active Pending
-
2022
- 2022-12-21 CL CL2022003689A patent/CL2022003689A1/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998050399A1 (en) | 1997-05-08 | 1998-11-12 | Corixa Corporation | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
WO2001034617A2 (en) | 1999-11-12 | 2001-05-17 | Corixa Corporation | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
WO2001036433A2 (en) | 1999-11-15 | 2001-05-25 | Biomira, Inc. | Synthetic lipid-a analogs and uses thereof |
WO2004062599A2 (en) | 2003-01-06 | 2004-07-29 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
US20080188566A1 (en) | 2007-02-01 | 2008-08-07 | Pan Thera Biopharma,Llc | Hydroxamic acid derivatives of 3-Phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning |
WO2016109880A1 (en) * | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
WO2019157509A1 (en) * | 2018-02-12 | 2019-08-15 | Inimmune Corporation | Toll-like receptor ligands |
Non-Patent Citations (22)
Title |
---|
"Molecular Cloning", 1989, COLD SPRING HARBOR LABORATORY PRESS |
"Peptide Synthesis", 1966, INTERSCIENCE |
"Series of Experimental Chemistry", vol. 14, 2005, JIKKEN KAGAKU KOUZA, pages: 11 - 16 |
"The Proteins", vol. 2, 1976, ACADEMIC PRESS INC. |
BERMAN PW ET AL., SCIENCE, vol. 227, 1985, pages 1490 |
BIOORG MED CHEM LETT, vol. 25, no. 3, 1 February 2015 (2015-02-01), pages 547 - 53 |
CANCER IMMUNOL IMMUNOTHER, vol. 52, no. 10, October 2003 (2003-10-01), pages 608 - 16 |
CERVARIX INTERVIEW FORM |
FREY SE ET AL., INFECT DIS, vol. 180, 1999, pages 1700 |
GONCZOL E. ET AL., EXP. OPIN. BIOL. THER., vol. 1, 2001, pages 401 |
J BIOL CHEM., vol. 279, no. 6, 6 February 2004 (2004-02-06), pages 4440 - 9 |
J LIPOSOME RES, vol. 14, no. 3-4, 2004, pages 175 - 89 |
JAGER E ET AL., INT. J. CANCER, vol. 67, 1996, pages 54 |
MICROBES INFECT, vol. 4, no. 8, July 2002 (2002-07-01), pages 837 - 51 |
NATURE, vol. 458, no. 7242, 30 April 2009 (2009-04-30), pages 1191 - 5 |
PLOS ONE, vol. 5, no. 3, pages e9809 |
REGUL TOXICOL PHARMACOL, vol. 35, no. 3, June 2002 (2002-06-01), pages 398 - 413 |
ROSA CL ET AL., BLOOD, vol. 100, 2002, pages 3681 |
SCHEIBENBOGEN C ET AL., J. IMMUNOTHER, vol. 23, 2000, pages 275 |
SMITH JWI ET AL., J. CLIN. ONCOL., vol. 21, 2003, pages 1562 |
VACCINE, vol. 31, no. 42, 1 October 2013 (2013-10-01), pages 4827 - 33 |
VAN DRIEL WJ ET AL., EUR. J. CANCER, vol. 35, 1999, pages 946 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2021261444A1 (ja) | 2021-12-30 |
KR20230026438A (ko) | 2023-02-24 |
US20230287027A1 (en) | 2023-09-14 |
CN116056721A (zh) | 2023-05-02 |
EP4169527A1 (en) | 2023-04-26 |
BR112022025969A2 (pt) | 2023-01-17 |
CA3187828A1 (en) | 2021-12-30 |
PE20230463A1 (es) | 2023-03-14 |
AU2021295796A1 (en) | 2023-02-02 |
IL299253A (en) | 2023-02-01 |
MX2022016181A (es) | 2023-02-13 |
CL2022003689A1 (es) | 2023-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108290845B (zh) | 嘧啶化合物 | |
JP7053106B2 (ja) | リピドa模倣体、調製方法、及びその使用 | |
DK2931738T3 (en) | COMPOSITIONS INCLUDING CYCLIC PURINDINUCLEOTIDES WITH DEFINED STEREOCHEMISTRY AND METHODS FOR PREPARING AND USING THEREOF | |
AU2018361867B2 (en) | Brartemicin analogues | |
Hussein et al. | Double conjugation strategy to incorporate lipid adjuvants into multiantigenic vaccines | |
CN108348618B (zh) | 腺嘌呤缀合物化合物及其作为疫苗佐剂的用途 | |
WO2020204172A1 (ja) | 水溶性アジュバント | |
CN108883080B (zh) | 胞壁酰肽衍生物化合物、其合成及其用途 | |
WO2021261444A1 (ja) | Tlr4作動活性を有するアジュバント | |
JP7448954B2 (ja) | ジアリールトレハロース化合物及びその使用 | |
OA21080A (en) | Adjuvant with TLR4 agonist activity. | |
US20220056080A1 (en) | Muramyl Peptide Derivatives | |
WO2023211930A1 (en) | Dual functioning immune modulating compounds, formulations, and uses thereof | |
JP2021525773A (ja) | Tlr7ペプチドコンジュゲート |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21829834 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022531976 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3187828 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112022025969 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237001883 Country of ref document: KR Kind code of ref document: A Ref document number: 112022025969 Country of ref document: BR Kind code of ref document: A2 Effective date: 20221219 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021829834 Country of ref document: EP Effective date: 20230123 |
|
ENP | Entry into the national phase |
Ref document number: 2021295796 Country of ref document: AU Date of ref document: 20210621 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522441781 Country of ref document: SA |